

01-29-00  
A Box SQ  
DOCKET NO.: RTS-0066

"Express Mail" Label No.: EL263652525US  
Date of Deposit: 1/24/2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: C. Frank Bennett, Nicholas M. Dean and Lex M. Cowser

For: **Antisense Modulation of nitric oxide synthase - inducible Expression**

BOX SEQUENCE

Assistant Commissioner for Patents  
Washington DC 20231

PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find the following:

- The specification of the above-referenced patent application;
- An **executed** Declaration or Oath and Power of Attorney;
- An Assignment of the invention to **Isis Pharmaceuticals Inc.** with recordation cover sheet (PTO Form PTO-1595) and \$40.00 cover fee;
- An **executed** Verified Statement Claiming Small Entity Status under 37 CFR 1.9 and 1.27;
- Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR § § 1.821 through 1.825;
- Sequence listing in computer readable form in accordance with 37 C.F.R. § 1.821(e); and
- An Information Disclosure Statement with references.

The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Rate	Fee
BASE FEE				\$345.00
Total Claims	17 - 20 =	0	X \$9=	\$0
Indep. Claims	1 - 3 =	0	x\$39=	\$0
TOTAL				\$ 345.00

The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 500252:

- the amount of \$385.00 for the above listed fees;
- payment of the following fees associated with this communication or credit any overpayment;
- any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims; and
- any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20 (d).

Triplicate copies of this transmittal are enclosed.

Date:

January 24, 2000

*Laurel Spear Bernstein*  
Laurel Spear Bernstein  
Registration No. 37,280  
Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Jane Massey Licata  
Law Offices of Jane Massey Licata  
66 East Main Street  
Marlton NJ 08053  
(609) 810-1515

Applicant or Patentee: C. Frank Bennett, Nicholas M. Dean and Lex M. Cowser

Serial or Patent No.: not yet assigned

Date Filed or Issued: herewith

For: Antisense Modulation of nitric oxide synthase - inducible Expression

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) and 1.27(c) - SMALL BUSINESS CONCERN)**

I hereby declare that I am an official empowered to act on behalf of the concern identified below:

NAME OF CONCERN: Isis Pharmaceuticals Inc.  
 ADDRESS OF CONCERN: 2922 Faraday Ave  
 Carlsbad, California 92008

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that: (1) the number of employees of the concern, including those of its affiliates, does not exceed 500 persons; and (2) the concern has not assigned, granted, conveyed, or licensed, and is under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern or a nonprofit organization under this section.

For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled **Antisense Modulation of nitric oxide synthase - inducible Expression** by inventor(s) C. Frank Bennett, Nicholas M. Dean and Lex M. Cowser described in the specification filed herewith.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statements are required for each named person, concern or organization having rights to the invention averring to their status as small entities.  
 (37 CFR 1.27)

FULL NAME: ( ) INDIVIDUAL ( ) SMALL BUSINESS CONCERN  
 ADDRESS: ( ) NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING  
 TITLE OF PERSON SIGNING  
 ADDRESS OF PERSON SIGNING

C. Frank Bennett  
 Vice President, Biology  
 2292 Faraday Avenue  
 Carlsbad, CA 92008

C. Frank Bennett  
 SIGNATURE

1-17-2000  
 DATE

## ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION

### FIELD OF THE INVENTION

The present invention provides compositions and methods for modulating the expression of inducible nitric oxide synthase. In particular, this invention relates to antisense compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding inducible nitric oxide synthase. Such oligonucleotides have been shown to modulate the expression of inducible nitric oxide synthase.

### BACKGROUND OF THE INVENTION

Nitric Oxide (NO) is a short-lived second messenger that exhibits a diverse array of effects within the normal cell including the regulation of neurotransmission, vasodilation, immunological processes and antimicrobial defenses. Due to its radical properties, however, NO has also been implicated in the onset and maintenance of several pathological conditions. Nitric oxide is produced constitutively in most cell types at low concentrations but levels are greatly increased in response to cellular stimulation by cytokines or bacterial products. Nitric oxide is generated from the amino acid L-arginine by the enzymatic activity of nitric oxide synthase (NOS) (Kroncke et al., *Clin. Exp. Immunol.*, **1998**, 113, 147-156; Marletta et al., *Curr. Opin. Chem. Biol.*, **1998**, 2, 656-663).

Three isoforms of the NOS enzyme have been isolated and the differential regulation of these isoforms mediates the fluctuating levels of nitric oxide present within quiescent

and stimulated cells. Two of the three isoforms, found in brain and endothelium, are calcium and calmodulin dependent and are responsible for the constitutive levels of nitric oxide present in cells. The third isoform is calcium independent and is expressed after transcriptional induction by several stimuli resulting in localized bursts of nitric oxide production. Because of the highly reactive and potentially toxic nature of the nitric oxide molecule and because relatively high concentrations are generated by the inducible form of the NOS enzyme, much effort has been focused on the control of nitric oxide levels in cells through the regulation of this enzyme (Kroncke et al., *Clin. Exp. Immunol.*, **1998**, 113, 147-156; Marletta et al., *Curr. Opin. Chem. Biol.*, **1998**, 2, 656-663).

Inducible nitric oxide synthase (also known as iNOS) was first isolated from human hepatocytes, articular chondrocytes and bone cells with mRNA levels being elevated upon stimulation with lipopolysaccharides (LPS) cytokines and interleukin 1 (IL-1) (Geller et al., *Proc. Natl. Acad. Sci. U. S. A.*, **1993**, 90, 3491-3495; Maier et al., *Biochim. Biophys. Acta.*, **1994**, 1208, 145-150). More recently, a splice variant of human iNOS (GenBank accession number AB022318) was isolated from an osteoblastoma cell line.

Mice lacking the iNOS gene have been developed and shown to be viable and fertile (Casey et al., *Transplantation*, **1997**, 64, 589-593; Laubach et al., *Proc. Natl. Acad. Sci. U. S. A.*, **1995**, 92, 10688-10692). However, lymphocytes from iNOS knockouts showed increased proliferative responses and production of cytokines (interferon-gamma, IL-2 and IL-12) in response to allogeneic antigen (Casey et al., *Transplantation*, **1997**, 64, 589-593) and studies on macrophages from the null mice show a failure to restrict the growth of lymphoma cells post-infection (MacMicking et al., **1998**; MacMicking et al., *Cell*, **1995**, 81, 641-650). In addition, disclosed in US Patent 5,766,909 are a DNA molecule

encoding murine iNOS, an expression vector encoding iNOS and methods to produce recombinant iNOS (Xie et al., 1998).

Manifestations of increased nitric oxide production and altered iNOS expression appear in both injury and disease states. Several studies have correlated increased iNOS expression with disorders such as congestive heart failure, CNS disorders, and diabetes (Lee and Brosnan, *Methods*, 1996, 10, 31-37; Rabinovitch et al., *Endocrinology*, 1996, 137, 2093-2099; Vejlstrup et al., *J. Mol. Cell. Cardiol.*, 1998, 30, 1215-1223).

Currently, strategies aimed at modulating iNOS expression and function involve the use of antibodies, antisense technology, chemical inhibitors and gene knock-outs in mice.

Studies using antisense oligonucleotides to effectively reduce the mRNA levels of iNOS in animal models have been reported in the literature. In a rat model of septic shock, antisense oligonucleotides targeted to iNOS were shown to prevent LPS-induced hyporeactivity to norepinephrine (Hoque et al., *Am. J. Physiol.*, 1998, 275, H1078-1083). In a mouse model of multiple sclerosis, administration of an antisense phosphorothioate oligonucleotides against mouse iNOS blocked the induction of iNOS mRNA and protein expression in glial cells and inhibited the induction of experimental autoimmune encephalomyelitis (EAE) (Ding et al., *J. Immunol.*, 1998, 160, 2560-2564; Ding et al., *Neurosci. Lett.*, 1996, 220, 89-92). Phosphorothioate antisense oligonucleotides targeting iNOS were also used to demonstrate the toxic role of nitric oxide in ischemic acute renal failure in the rat (Noiri et al., *J. Clin. Invest.*, 1996, 97, 2377-2383). In studies to investigate the role of nitric oxide in cell adhesion, macrophages expressing either the sense or antisense murine iNOS construct were characterized. It was found that cells expressing the antisense iNOS produced 22-97% less nitric oxide than sense lines (Cartwright et al., *Br. J. Pharmacol.*, 1997, 120, 146-152).

In human cell lines, an antisense oligonucleotide 32 nucleotides long targeted to iNOS has also been used to discern the role of iNOS in the processes of apoptosis (Selleri et al., *Br. J. Haematol.*, **1997**, 99, 481-489). An antisense oligonucleotide targeted to nucleotides 62-85 of human iNOS has been used to study the role of this enzyme in oxidative stress injury (Peresleni et al., *Am. J. Physiol.*, **1996**, 270, F971-977).

Various types of inhibitors of iNOS function, including chemical moieties and naturally occurring molecules such as amino acids and peptide fragments, have been investigated and characterized in the art. Disclosed in US Patents 5,028,627 and 5,216,025 are methods to treat systemic hypotension in septic and cytokine-treated patients using arginine derivatives to decrease nitrogen oxide production (Gross et al., **1993**; Kilbourn et al., **1991**). The use of arginine derivatives to suppress iNOS function is also reported in PCT publication number WO 98/48826 (Silverman et al., **1998**). Disclosed in PCT publication numbers WO 93/13055 and WO 96/19440 are amidino and acetamide derivative inhibitors of iNOS, respectively (Beams et al., **1993**; Oplinger et al., **1996**).

Other inhibitors include a peptide nucleic acid derivative with a base sequence complementary to the homopurine region at nucleotides 238-251 of mouse iNOS (Giovine et al., *FEBS Lett.*, **1998**, 426, 33-36), aminoguanidine (Corbett and McDaniel, *Methods*, **1996**, 10, 21-30), N- $\alpha$ -Tosyl-L-Lysine chloromethylketone (Schini-Kerth et al., *Arterioscler. Thromb. Vasc. Biol.*, **1997**, 17, 672-679), gadolinium chloride (Roland et al., *J. Leukoc. Biol.*, **1996**, 60, 487-492), taurine chloramine (Park et al., *J. Leukoc. Biol.*, **1997**, 61, 161-166), di-catechol rooperol (Bereta et al., *Life Sci.*, **1997**, 60, 325-334), tyrosine kinase inhibitors (Corbett et al., *Am. J. Physiol.*, **1996**, 270, C1581-1587) and immunosuppressive drugs (Cai et al., *Int. J.*

*Cardiol.*, **1995**, *50*, 243-251). Furthermore, disclosed in US Patent 5,789,395 are methods to inhibit nitric oxide production using tetracycline compounds (Amin et al., **1998**) and in US Patent 5,695,761 methods of treating an inflammatory disease by administering epitopes of the protein osteopontin are disclosed (Denhardt et al., **1997**).

Recently, iNOS inhibitors intended to treat various human conditions including CNS disease, ischemia/reperfusion injury and opioid tolerance that occurs as a result of sustained opioid usage during chronic pain have been reported in the art (Maeda et al., **1998**; Salvemini, **1998**; Singh, **1998**).

Finally, disclosed in EP 94304174 is a pharmaceutical composition comprising a combination of an iNOS inhibitor and anti-inflammatory agent for the treatment of systemic inflammatory response syndrome (Teale, **1994**).

Despite the variety of iNOS inhibitors disclosed in the art, there still remains a need for therapeutic agents capable of effectively and specifically inhibiting the function of the inducible isoform of the NOS enzyme (iNOS).

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of iNOS expression.

#### **SUMMARY OF THE INVENTION**

The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding inducible nitric oxide synthase, and which modulate the expression of inducible nitric oxide synthase. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the expression of inducible nitric oxide synthase in cells or tissues

comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of inducible nitric oxide synthase by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding inducible nitric oxide synthase, ultimately modulating the amount of inducible nitric oxide synthase produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding inducible nitric oxide synthase. As used herein, the terms "target nucleic acid" and "nucleic acid encoding inducible nitric oxide synthase" encompass DNA encoding inducible nitric oxide synthase, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of inducible



[illegible]

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding inducible nitric oxide synthase. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the

art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding inducible nitric oxide synthase, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon,

and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between

two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 25 nucleobases. As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further

include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3'

or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application, and each of

which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, **1991**, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular  $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$ ,  $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$  [known as a methylene (methylinino) or MMI backbone],  $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$ ,  $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$  and  $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$  [wherein the native phosphodiester backbone is represented as  $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$ ] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may



be substituted or unsubstituted  $C_1$  to  $C_{10}$  alkyl or  $C_2$  to  $C_{10}$  alkenyl and alkynyl. Particularly preferred are  $O[(CH_2)_nO]_mCH_3$ ,  $O(CH_2)_nOCH_3$ ,  $O(CH_2)_nNH_2$ ,  $O(CH_2)_nCH_3$ ,  $O(CH_2)_nONH_2$ , and  $O(CH_2)_nON[(CH_2)_nCH_3]_2$ , where  $n$  and  $m$  are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position:  $C_1$  to  $C_{10}$  lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH<sub>3</sub>, OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, **1995**, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminooxyethoxy, i.e., a  $O(CH_2)_2ON(CH_3)_2$  group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>2</sub>, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785;

5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909;  
5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873;  
5,670,633; and 5,700,920, certain of which are commonly owned  
with the instant application, and each of which is herein  
incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, **1990**, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, **1991**, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B. , ed., CRC Press, **1993**. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-

6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, **1993**, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, **1989**, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1994**, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1993**, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, 259, 327-330; Svinarchuk et al., *Biochimie*, **1993**, 75, 49-54), a

phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, 277, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly

oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the

well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules. The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphatate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, **1977**, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or

inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylemaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and



spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of inducible nitric oxide synthase is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding inducible nitric oxide synthase, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding inducible nitric oxide synthase can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits

using such detection means for detecting the level of inducible nitric oxide synthase in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not

limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions

and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

#### Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1  $\mu\text{m}$  in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, **1985**, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and

water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., **1988**, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different

classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions

Approved by the FDA

by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined

as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., **1989**, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, **1985**, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.



Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprates (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, **1994**, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, **1993**, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug

absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, **1994**, 11, 1385; Ho et al., *J. Pharm. Sci.*, **1996**, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, p. 92). Each of these classes has been discussed above.

#### Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles,

bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal

contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang *et al.*, *Biochem. Biophys. Res. Commun.*, **1987**, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou *et al.*, *Journal of Controlled Release*, **1992**, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner *et al.*, *Journal of Drug Targeting*, **1992**, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis *et al.*, *Antiviral Research*, **1992**, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu *et al.* *S.T.P. Pharma. Sci.*, **1994**, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside  $G_{M1}$ , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen *et al.*, *FEBS Letters*, **1987**, 223, 42; Wu *et al.*, *Cancer Research*, **1993**, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos *et al.* (*Ann. N.Y. Acad. Sci.*, **1987**, 507, 64) reported the ability of monosialoganglioside  $G_{M1}$ , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon *et al.* (*Proc. Natl. Acad. Sci. U.S.A.*, **1988**, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen *et al.*, disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside  $G_{M1}$  or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb *et al.*) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim *et al.*).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto *et al.* (*Bull. Chem. Soc. Jpn.*, **1980**, 53, 2778) described liposomes comprising a

nonionic detergent, 2C<sub>12</sub>15G, that contains a PEG moiety. Illum *et al.* (*FEBS Lett.*, **1984**, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov *et al.* (*FEBS Lett.*, **1990**, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume *et al.* (*Biochimica et Biophysica Acta*, **1990**, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle *et al.* (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin *et al.* (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin *et al.*) and in WO 94/20073 (Zalipsky *et al.*) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi *et al.*). U.S. Patent Nos. 5,540,935 (Miyazaki *et al.*) and 5,556,948 (Tagawa *et al.*) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry *et al.* discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa *et al.* discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense

RNA. U.S. Patent No. 5,665,710 to Rahman *et al.* describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love *et al.* discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, *e.g.* they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their



structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid,

linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C<sub>10</sub> alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, **1992**, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, **1996**, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, **1990**, pages 782-783; Muranishi,

SECRET

*Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, **1992**, 263, 25; Yamashita et al., *J. Pharm. Sci.*, **1990**, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, **1993**, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Buur et al., *J. Control Rel.*, **1990**, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92); and non-steroidal anti-

inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

#### Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (*i.e.*, does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-

disulfonic acid (Miyao *et al.*, *Antisense Res. Dev.*, **1995**, 5, 115-121; Takakura *et al.*, *Antisense & Nucl. Acid Drug Dev.*, **1996**, 6, 177-183).

#### Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, *etc.*, when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, *etc.*); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, *etc.*); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, *etc.*); disintegrants (e.g., starch, sodium starch glycolate, *etc.*); and wetting agents (e.g., sodium lauryl sulphate, *etc.*).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

#### Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do

not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., **1987**, Rahway, N.J., pages 1206-1228). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., **1987**, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of

Approved for Release



antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on  $EC_{50}$ s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

**EXAMPLES****Example 1****Nucleoside Phosphoramidites for Oligonucleotide Synthesis  
Deoxy and 2'-alkoxy amidites**

2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, **1993**, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA).

**2'-Fluoro amidites****2'-Fluorodeoxyadenosine amidites**

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, **1993**, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S<sub>N</sub>2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups

was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

### **2'-Fluorodeoxyguanosine**

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

### **2'-Fluorouridine**

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

### **2'-Fluorodeoxycytidine**

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

### **2'-O-(2-Methoxyethyl) modified amidites**

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, **1995**, 78, 486-504.

**2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]**

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

**2'-O-Methoxyethyl-5-methyluridine**

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH<sub>3</sub>CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH<sub>2</sub>Cl<sub>2</sub>/acetone/MeOH (20:5:3) containing 0.5% Et<sub>3</sub>NH.

The residue was dissolved in  $\text{CH}_2\text{Cl}_2$  (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with  $\text{CH}_3\text{CN}$  (200 mL). The residue was dissolved in  $\text{CHCl}_3$  (1.5 L) and extracted with 2x500 mL of saturated  $\text{NaHCO}_3$  and 2x500 mL of saturated  $\text{NaCl}$ . The organic phase was dried over  $\text{Na}_2\text{SO}_4$ , filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with  $\text{EtOAc}$ /hexane/acetone (5:5:1) containing 0.5%  $\text{Et}_3\text{NH}$ . The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged

by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl<sub>3</sub> (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl<sub>3</sub>. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine**

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH<sub>3</sub>CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH<sub>3</sub>CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl<sub>3</sub> was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO<sub>3</sub> and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH<sub>4</sub>OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated

and the residue azeotrope with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with  $\text{NH}_3$  gas was added and the vessel heated to  $100^\circ\text{C}$  for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotrope with MeOH (200 mL). The residue was dissolved in  $\text{CHCl}_3$  (700 mL) and extracted with saturated  $\text{NaHCO}_3$  (2x300 mL) and saturated NaCl (2x300 mL), dried over  $\text{MgSO}_4$  and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5%  $\text{Et}_3\text{NH}$  as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite**

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in  $\text{CH}_2\text{Cl}_2$  (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated  $\text{NaHCO}_3$  (1x300 mL) and saturated NaCl

(3x300 mL). The aqueous washes were back-extracted with  $\text{CH}_2\text{Cl}_2$  (300 mL), and the extracts were combined, dried over  $\text{MgSO}_4$  and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

**2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites**

**2'-(Dimethylaminooxyethoxy) nucleoside amidites**

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

**5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine**

O<sup>2</sup>-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. *tert*-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (R<sub>f</sub> 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved



in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

**5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine**

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-0<sup>2</sup>-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure

recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

**2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine**

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P<sub>2</sub>O<sub>5</sub> under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

**5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine**

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH<sub>2</sub>Cl<sub>2</sub> and the combined organic phase was washed with water, brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for

1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%).

**5'-O-*tert*-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine**

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). Aqueous NaHCO<sub>3</sub> solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO<sub>3</sub> (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

**2'-O-(dimethylaminoxyethyl)-5-methyluridine**

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

**5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine**

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P<sub>2</sub>O<sub>5</sub> under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

**5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P<sub>2</sub>O<sub>5</sub> under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N<sup>1</sup>,N<sup>1</sup>-tetrakisopropylphosphoramidite (2.12mL, 6.08mmol) was added.

The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO<sub>3</sub> (40mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

### **2'-(Aminooxyethoxy) nucleoside amidites**

2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

### **N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinasso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before

the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

#### **2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites**

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>2</sub>, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

#### **2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O<sup>2</sup>-,2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

#### **5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2x200 mL). The combined CH<sub>2</sub>Cl<sub>2</sub> layers are washed with saturated NaHCO<sub>3</sub> solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>3</sub>N (20:1, v/v, with 1% triethylamine) gives the title compound.

**5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite**

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

**Example 2**

**Oligonucleotide synthesis**

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation

wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution.

Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

### **Example 3**

#### **Oligonucleoside Synthesis**

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked



oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

#### **Example 4**

##### **PNA Synthesis**

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, **1996**, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

#### **Example 5**

##### **Synthesis of Chimeric Oligonucleotides**

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of

the second type are also known in the art as "hemimers" or "wingmers".

**[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric  
Phosphorothioate Oligonucleotides**

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

**[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate  
Oligonucleotides**

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-

(methoxyethyl) amidites for the 2'-O-methyl amidites.

**[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy  
Phosphorothioate]--[2'-O-(2-Methoxyethyl)  
Phosphodiester] Chimeric Oligonucleotides**

[2'-O-(2-methoxyethyl phosphodiester)--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

**Example 6**

**Oligonucleotide Isolation**

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by <sup>31</sup>P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with

HPLC-purified material were similar to those obtained with non-HPLC purified material.

#### **Example 7**

##### **Oligonucleotide Synthesis - 96 Well Plate Format**

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated  $\text{NH}_4\text{OH}$  at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

#### **Example 8**

##### **Oligonucleotide Analysis - 96 Well Plate Format**

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone

composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

### **Example 9**

#### **Cell culture and oligonucleotide treatment**

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 6 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

#### **T-24 cells:**

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates

and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

MCF-7 cells:

The human breast carcinoma cell line MCF-7 was obtained from the American Type Culture Collection (Manassas, VA). MCF-7 cells were routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg,

MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

#### LA4 cells:

The mouse lung epithelial cell line LA4 was obtained from the American Type Culture Collection (Manassas, VA). LA4 cells were routinely cultured in F12K medium (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 15% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 3000-6000 cells/ well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

#### Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200  $\mu$ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130  $\mu$ L of OPTI-MEM™-1 containing 3.75  $\mu$ g/mL LIPOFECTIN™ (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at

a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCCAAGGA**, SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

#### Example 10

##### **Analysis of oligonucleotide inhibition of inducible nitric oxide synthase expression**

Antisense modulation of inducible nitric oxide synthase expression can be assayed in a variety of ways known in the art. For example, inducible nitric oxide synthase mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred.

RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et



al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed as multiplexable. Other methods of PCR are also known in the art.

Protein levels of inducible nitric oxide synthase can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to inducible nitric oxide synthase can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons,

Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

#### **Example 11**

##### **Poly(A)+ mRNA isolation**

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold PBS. 60  $\mu$ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55  $\mu$ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200  $\mu$ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes.

60  $\mu$ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

### Example 12

#### Total RNA Isolation

Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold PBS. 100  $\mu$ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100  $\mu$ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60  $\mu$ L water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60  $\mu$ L water.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

### **Example 13**

#### **Real-time Quantitative PCR Analysis of inducible nitric oxide synthase mRNA Levels**

Quantitation of inducible nitric oxide synthase mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE, FAM, or VIC, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of

Parameter	Value	Unit
$\alpha$	0.001	
$\beta$	0.001	
$\gamma$	0.001	
$\delta$	0.001	
$\epsilon$	0.001	
$\zeta$	0.001	
$\eta$	0.001	
$\theta$	0.001	
$\iota$	0.001	
$\kappa$	0.001	
$\lambda$	0.001	
$\mu$	0.001	
$\nu$	0.001	
$\xi$	0.001	
$\omicron$	0.001	
$\pi$	0.001	
$\rho$	0.001	
$\sigma$	0.001	
$\tau$	0.001	
$\upsilon$	0.001	
$\phi$	0.001	
$\chi$	0.001	
$\psi$	0.001	
$\omega$	0.001	
$\Omega$	0.001	
$\Theta$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	
$\Phi$	0.001	
$\Psi$	0.001	
$\Xi$	0.001	
$\Omicron$	0.001	
$\Pi$	0.001	
$\Sigma$	0.001	
$\Upsilon$	0.001	

Probes and primers to human inducible nitric oxide synthase were designed to hybridize to a human inducible nitric oxide synthase sequence, using published sequence information (GenBank accession number L09210, incorporated herein as SEQ ID NO:3). For human inducible nitric oxide synthase the PCR primers were:

forward primer: GGTGGAAGCGGTAACAAAGGA (SEQ ID NO: 4)  
reverse primer: TGCTTGGTGGCGAAGATGA (SEQ ID NO: 5) and the  
PCR probe was: FAM-AACAACAGGAACCTACCAACTGACGGGAGA-TAMRA

(SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 7)

reverse primer: GAAGATGGTGATGGGATTTTC (SEQ ID NO: 8) and the PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 9) where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

Probes and primers to mouse inducible nitric oxide synthase were designed to hybridize to a mouse inducible nitric oxide synthase sequence, using published sequence information (GenBank accession number M92649, incorporated herein as SEQ ID NO:10). For mouse inducible nitric oxide synthase the PCR primers were:

forward primer: CGTCCACAGTATGTGAGGATCAA (SEQ ID NO:11)

reverse primer: CAAGCAAGACTTGGACTTGCAA (SEQ ID NO: 12) and the PCR probe was: FAM-TCTTCACCACAAGGCCACATCGGATT-TAMRA (SEQ ID NO: 13) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

For mouse GAPDH the PCR primers were:

forward primer: GGCAAATTCACGGCACAGT (SEQ ID NO: 14)

reverse primer: GGGTCTCGCTCCTGGAAGCT (SEQ ID NO: 15) and the PCR probe was: 5' JOE-AAGGCCGAGAATGGGAAGCTTGTCATC- TAMRA 3' (SEQ ID NO: 16) where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

#### **Example 14**

##### **Northern blot analysis of inducible nitric oxide synthase mRNA levels**

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was

prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent conditions.

To detect human inducible nitric oxide synthase, a human inducible nitric oxide synthase specific probe was prepared by PCR using the forward primer GGTGGAAGCGGTAACAAAGGA (SEQ ID NO: 4) and the reverse primer TGCTTGGTGGCGAAGATGA (SEQ ID NO: 5). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

To detect mouse inducible nitric oxide synthase, a mouse inducible nitric oxide synthase specific probe was prepared by PCR using the forward primer CGTCCACAGTATGTGAGGATCAA (SEQ ID NO: 11) and the reverse primer CAAGCAAGACTTGGACTTGCAA (SEQ ID NO: 12). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

**Example 15****Antisense inhibition of human inducible nitric oxide synthase expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap**

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human inducible nitric oxide synthase RNA, using published sequences (GenBank accession number L09210, incorporated herein as SEQ ID NO: 3, and GenBank accession number L07868, incorporated herein as SEQ ID NO: 17). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 18 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by four-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. Cytidine residues in the 2'-MOE wings are 5-methylcytidines for ISIS 24032 through 24071. All cytidine residues are 5-methylcytidines for ISIS 19631 through 19714. The compounds were analyzed for their effect on human inducible nitric oxide synthase mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

Inhibition of human inducible nitric oxide synthase mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
24032	5'UTR	3	14	catcaaagggtggccgaga	76	19



24033	5'UTR	3	38	ctgtctagaactgccag	50	20
24034	5'UTR	3	57	tgccctgagaacttcggg	41	21
24035	5'UTR	3	160	tgctacttatctggattt	17	22
24036	Coding	3	219	cttgaacagaaatttcca	34	23
24037	Coding	3	277	tctccacattgttgttga	43	24
24038	Coding	3	338	ctgaggttgtgatactga	16	25
24039	Coding	3	410	agcttgaccagagattct	19	26
24040	Coding	3	492	gtgaagtgtgtcttggaa	13	27
24041	Coding	3	534	gcaagatttggacctgca	0	28
24042	Coding	3	580	cctgggtcctcttggtca	74	29
24043	Coding	3	645	gccgtaatatgtgtgac	55	30
24044	Coding	3	705	ctccttgtttaccgcttc	53	31
24045	Coding	3	745	gctcatctcccgtcagtt	55	32
24046	Coding	3	823	agacctgcaggttggacc	42	33
24047	Coding	3	880	cgtgtctgcagatgtgtt	0	34
24048	Coding	3	959	aagtcgtgcttgccatca	0	35
24049	Coding	3	1025	cctctgatgctgccatct	33	36
24050	Coding	3	1098	atcgaagcggcgctactt	12	37
24051	Coding	3	1184	tccatggccacctcaagc	59	38
24052	Coding	3	1240	caggcaggcgctaccact	0	39
24053	Coding	3	1320	ctctgtgccccatgtacca	3	40
24054	Coding	3	1379	ctgccacttctctccagg	15	41
24055	Coding	3	1445	ttgatctcaacgacagcc	32	42
24056	Coding	3	1493	tccatgatggtcacattc	49	43
24057	Coding	3	1548	ggaccggtattcattctg	57	44
24058	Coding	3	1640	acgtagttcagcatctcc	65	45
24059	Coding	3	1713	gggtctccgcttctcgtc	58	46
24060	Coding	3	1772	agcatacaggcaagagc	0	47
24061	Coding	3	1830	tgtctctgtcgcaaagag	21	48
24062	Coding	3	1938	ttcctcctccaggcagct	48	49
24063	Coding	3	1994	ccattgccagggcagctct	38	50
24064	Coding	3	2059	acacagcgtacctgaatt	11	51
24065	Coding	3	2122	gcttctgatcaatgtcat	52	52
24066	Coding	3	2317	tgtagtgggtgcgggtccc	30	53
24067	Coding	3	2435	ctggatgtcggactttgt	35	54
24068	Coding	3	2642	ctcttgtcactgaccag	0	55
24069	3'UTR	3	3673	ctttaacccctctgtag	19	56
24070	3'UTR	3	3689	agttctgtgcggcagct	45	57
24071	3'UTR	3	3722	acctcagataatgcagag	31	58
19631	5'UTR	17	2	agatcccgtgctgacaat	48	59
19632	Coding	17	51	ctcaccagagaccaaagt	33	60
19633	Coding	17	72	gtccccgcgcgccacgaga	42	61
19634	Coding	17	99	actgactgagaatcgctg	51	62
19635	Coding	17	151	ctgctgttccagggtcaga	73	63
19636	Coding	17	213	gttatcttcagggtgcc	44	64
19637	Coding	17	232	cgggttctgtctcaatgct	47	65
19638	Coding	17	307	caggtaacgaaactgatt	40	66
19639	Coding	17	319	attctccagaggcaggta	68	67
19640	Coding	17	351	tcataaagttttgtccca	40	68
19641	Coding	17	408	agtccaaagtttccatct	59	69
19642	Coding	17	447	tttaggatttctgtcaag	35	70
19643	Coding	17	463	tacatagactccaccatt	30	71
19644	Coding	17	566	aactaccattttgttgaca	0	72
19645	Coding	17	577	tccacatctgaactacc	26	73
19646	Coding	17	632	ggcaatgattttctgtgg	34	74
19647	Coding	17	648	gtccttgtcaaagtcctgg	61	75
19648	Coding	17	682	gtagcatctgccgtcaca	52	76

19649	Coding	17	727	gcctccagcacattctcgc	82	77
19650	Coding	17	738	ggctcctgagcagcctcca	95	78
19651	Coding	17	760	ggcaaagcagtcctgtgtc	65	79
19652	Coding	17	833	aggtgggttgattgtaga	47	80
19653	Coding	17	850	attgtgctccagttgaaa	40	81
19654	Coding	17	900	tgtggacatttcttgaca	44	82
19655	Coding	17	944	tagggcaggcacgcacac	47	83
19656	Coding	17	978	ttaatcccatTTTTCTTCT	36	84
19657	Coding	17	1039	tgatcctgtgccaatgcc	61	85
19658	Coding	17	1175	ctgggtctatggcttcaa	66	86
19659	Coding	17	1189	gacgttcagtttctctgg	69	87
19660	Coding	17	1325	ggataagcaaggacaggc	49	88
19661	Coding	17	1361	actggaactgtagagagg	35	89
19662	Coding	17	1413	aggttgctgttgctcagta	56	90
19663	Coding	17	1435	gttaatgggtatgataata	24	91
19664	Coding	17	1469	ttctctgggttgattgtgc	44	92
19665	Coding	17	1475	ttactatttctctggttga	52	93
19666	Coding	17	1542	ctggaacacagatgggtg	41	94
19667	Coding	17	1562	caggtccccaacagccat	16	95
19668	Coding	17	1598	tactgaagcggcgacacg	44	96
19669	Coding	17	1629	aggttacaagactctatg	0	97
19670	Coding	17	1667	tggagccatttctcaaact	35	98
19671	Coding	17	1713	aggccatcttccatcttc	49	99
19672	Coding	17	1905	ctagtgggaccgttacac	44	100
19673	Coding	17	2024	tcagaccacaatgacca	29	101
19674	Coding	17	2055	atgctcttcccttctaaca	12	102
19675	Coding	17	2126	ctgtgccactgggagtta	55	103
19676	Coding	17	2205	ccaaaagcacctgagcca	1	104
19677	Coding	17	2262	gccacaggaatcttcaca	55	105
19678	Coding	17	2390	tggttgggctcagacaca	30	106
19679	Coding	17	2464	tccaatgttatccttgtg	21	107
19680	Coding	17	2568	actaagacattacgggct	1	108
19681	Coding	17	2656	tcctccatcagcattgta	36	109
19682	Coding	17	2766	ccaaaggatcatcagttcc	19	110
19683	Coding	17	2890	catccaacatttgaccat	12	111
19684	Coding	17	2936	actcagcagccagttcct	0	112
19685	Coding	17	3016	gtcatttggaactgggaag	32	113
19686	Coding	17	3058	ttccaaatcctcttcac	0	114
19687	Coding	17	3113	gaggtgggatgttgaaag	0	115
19688	Coding	17	3233	cagcaaaacctccatctc	15	116
19689	Coding	17	3316	ctcagcagtagcacctg	31	117
19690	Coding	17	3393	tgggtgctactgtcctct	28	118
19691	Coding	17	3488	gtttgtctcgcataaggag	14	119
19692	Coding	17	3515	ccactggattcaggtatt	0	120
19693	Coding	17	3633	ggctcattcacataactca	13	121
19694	Coding	17	3701	ttgacagtatgttgttct	0	122
19695	Coding	17	3747	ttccagtagtcagggttg	16	123
19696	Coding	17	3780	tgctgaagggtgctccga	0	124
19697	Coding	17	3870	aggtattcaggattctct	22	125
19698	Coding	17	3922	tctgtaagggtggaggcgg	15	126
19699	3'UTR	17	4052	agtgtcaaaactactggc	25	127
19700	3'UTR	17	4107	gttcaagttaggtaagca	0	128
19701	3'UTR	17	4138	ctatcttttctctttcagt	0	129
19702	3'UTR	17	4171	atgcagagaaaatgaagaa	0	130
19703	3'UTR	17	4229	cagcattgccttacattt	29	131
19704	3'UTR	17	4334	gtgtttcaaccatctgct	31	132
19705	3'UTR	17	4420	tttgttctaattggaaact	0	133

19706	3'UTR	17	4608	cagagcaaaacaaaatga	0	134
19707	3'UTR	17	4809	aggatgaggggtgaagata	25	135
19708	3'UTR	17	4880	tactcttcagacaaccaa	0	136
19709	3'UTR	17	4921	gttttcctgaaccacaga	29	137
19710	3'UTR	17	4993	acatacccaatccagtgt	53	138
19711	3'UTR	17	5069	aaaatggagttcagaaaa	0	139
19712	3'UTR	17	5218	gcctctcatcatagtccc	36	140
19713	3'UTR	17	5365	gagttaccttctacttca	17	141
19714	3'UTR	17	5455	cacatttatttacaactt	10	142

As shown in Table 1, SEQ ID NOs 19, 20, 21, 23, 24, 29, 30, 31, 32, 33, 36, 38, 42, 43, 44, 45, 46, 48, 49, 50, 52, 53, 54, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 98, 99, 100, 101, 103, 105, 106, 107, 109, 113, 117, 118, 125, 127, 131, 132, 135, 137, 138 and 140 demonstrated at least 20% inhibition of human inducible nitric oxide synthase expression in this assay and are therefore preferred.

#### **Example 17**

##### **Antisense inhibition of mouse inducible nitric oxide synthase expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap.**

In accordance with the present invention, a second series of oligonucleotides were designed to target different regions of the mouse inducible nitric oxide synthase RNA, using published sequences (GenBank accession number M87039, incorporated herein as SEQ ID NO: 18). The oligonucleotides are shown in Table 2. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The

internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse inducible nitric oxide synthase mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 2

Inhibition of mouse inducible nitric oxide synthase mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
105449	5'UTR	18	30	gtaaagttgtgaccctggca	0	143
105450	5'UTR	18	226	ttgcacttctgctccaaatc	0	144
105451	Coding	18	281	ttggtaggatttgactttga	0	145
105452	Coding	18	373	ctcttaggggtcatcttgat	6	146
105453	Coding	18	456	tcgatgtcacatgcagcttg	16	147
105454	Coding	18	543	tgaaatccgatgtggccttg	52	148
105455	Coding	18	621	gggtaggcttgtctctgggt	0	149
105456	Coding	18	646	gcatgaggcaggagctcctc	0	150
105457	Coding	18	805	ttcctccaggccatcttggt	0	151
105458	Coding	18	1012	atgagctgtgaattccagag	26	152
105459	Coding	18	1106	cttcagcctaggctcgatgc	22	153
105460	Coding	18	1180	atttcaaagacctctggatc	0	154
105461	Coding	18	1292	ctccagtagcatgttggcca	0	155
105462	Coding	18	1448	ccagagggaggccagtgtgt	8	156
105463	Coding	18	1511	cacattctgcttctggaac	13	157
105464	Coding	18	1577	ggcccgggtactcattctgca	5	158
105465	Coding	18	1678	ggagataggacatagttcaa	0	159
105466	Coding	18	1721	ccagatgtgggtcttccagg	3	160
105467	Coding	18	1766	tctaaatcggatctctctcc	5	161
105468	Coding	18	1853	agtagcaaagaggactgtgg	6	162
105469	Coding	18	1992	tgcttgtcaccaccagcagt	0	163
105470	Coding	18	2118	actgagggtacatgctggag	0	164
105471	Coding	18	2231	gctgcggaaggcatcctcct	0	165
105472	Coding	18	2357	ctggatgagcctatatattgct	4	166
105473	Coding	18	2394	tgctgagggtctgttgagg	0	167
105474	Coding	18	2466	ggctggacttttcactctgc	22	168
105475	Coding	18	2519	gtagctgggccctcggtgc	0	169
105476	Coding	18	2607	gtgtaggacaatccacaact	12	170
105477	Coding	18	2703	tgagggttggtgagtggag	0	171
105478	Coding	18	2802	aggcctccaatctctgccta	0	172
105479	Coding	18	2873	ctcttcaagcacctccagga	16	173
105480	Coding	18	2925	agataggagctgcgacagc	0	174
105481	Coding	18	3021	catctcgggtgcggtaggtg	0	175

105482	Coding	18	3117	agccactgacacttcgcaca	12	176
105483	Coding	18	3266	gcacccaaacaccaagctca	0	177
105484	Coding	18	3351	agcctgtgtgcacctggaac	0	178
105485	Coding	18	3389	ctgaacgtagaccttgggtt	2	179
105486	Coding	18	3514	accagcttcttcaatgtggt	25	180
105487	Coding	18	3601	aagatatcttcatgataacg	20	181
105488	Coding	18	3669	agagcctcgtggctttgggc	0	182

As shown in Table 2, SEQ ID NOs 148, 152, 153, 168 and 180 demonstrated at least 20% inhibition of mouse inducible nitric oxide synthase expression in this experiment and are therefore preferred.

#### **Example 17**

##### **Western blot analysis of inducible nitric oxide synthase protein levels**

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to inducible nitric oxide synthase is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

**What is claimed is:**

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding inducible nitric oxide synthase, wherein said antisense compound specifically hybridizes with and inhibits the expression of inducible nitric oxide synthase.

2. The antisense compound of claim 1 which is an antisense oligonucleotide.

3. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 19, 20, 21, 23, 24, 29, 30, 31, 32, 33, 36, 38, 42, 43, 44, 45, 46, 48, 49, 50, 52, 53, 54, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 98, 99, 100, 101, 103, 105, 106, 107, 109, 113, 117, 118, 125, 127, 131, 132, 135, 137, 138, 140, 148, 152, 153, 168 or 180.

4. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. The antisense compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. The antisense compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. The antisense compound of claim 1 wherein the

antisense oligonucleotide is a chimeric oligonucleotide.

11. A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

12. The pharmaceutical composition of claim 11 further comprising a colloidal dispersion system.

13. The pharmaceutical composition of claim 11 wherein the antisense compound is an antisense oligonucleotide.

14. A method of inhibiting the expression of inducible nitric oxide synthase in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of inducible nitric oxide synthase is inhibited.

15. A method of treating a human having a disease or condition associated with inducible nitric oxide synthase comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of inducible nitric oxide synthase is inhibited.

16. The method of claim 15 wherein the disease or condition is diabetes.

17. The method of claim 15 wherein the disease or condition is an immunological disorder.

18. The method of claim 15 wherein the disease or condition is a cardiovascular disorder.

19. The method of claim 15 wherein the disease or condition is a neurologic disorder.

20. The method of claim 15 wherein the disease or condition is ischemia/reperfusion injury.

## ABSTRACT

Antisense compounds, compositions and methods are provided for modulating the expression of inducible nitric oxide synthase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding inducible nitric oxide synthase. Methods of using these compounds for modulation of inducible nitric oxide synthase expression and for treatment of diseases associated with expression of inducible nitric oxide synthase are provided.



## COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **Antisense Modulation of nitric oxide synthase - inducible Expression** the specification of which:

(XX) is attached hereto.

( ) was filed on \_\_\_\_\_ as Application Serial No. \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a-d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Country	Number	Date Filed	Priority Claimed		
			Yes	No	
			Yes	No	
			Yes	No	

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (pending, patented)

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Provisional Application No.	Filing Date

**DOCKET NO.: RTS-0066**

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Herb Boswell, Registration No. 27,311; Laurel Spear Bernstein, Registration No. 37,280; and Henry P. Wu, Registration No. 44,412 of ISIS Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, California 92008; and Jane Massey Licata, Registration No. 32,257, and Kathleen A. Tyrrell, Registration No. 38,350 of the firm of Law Offices of Jane Massey Licata, 66 East Main Street, Marlton NJ 08053.

Address all telephone calls and correspondence to:

Jane Massey Licata  
Law Offices of Jane Massey Licata  
66 East Main Street  
Marlton NJ 08053  
(609) 810-1515

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1	Full Name: C. Frank Bennett	Inventor's Signature: <i>C. Frank Bennett</i>	Date: 1-17-2000
	Residence: 1347 Cassins Street Carlsbad CA 92009	Citizenship: USA	
	Post Office Address:same as above		
2	Full Name: Nicholas M. Dean	Inventor's Signature: <i>N. M. Dean</i>	Date:
	Residence: 2110 Whisperwind Lane Olivenhain CA 92024	Citizenship: USA UK <i>NMD</i>	1/17/00
	Post Office Address:same as above		
3	Full Name: Lex M. Cowser	Inventor's Signature: <i>L. M. Cowser</i>	Date: 1/17/00
	Residence: 3008 Newshire Street Carlsbad CA 92008	Citizenship: USA	
	Post Office Address: same as above		

## SEQUENCE LISTING

<110> C. Frank Bennett  
Nicholas M. Dean  
Lex M. Cowsert

&lt;120&gt; ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION

<130> RTS-0066

<160> 182

 $\langle 210 \rangle$  1

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

 $\langle 400 \rangle$  1

tccgtcatcg ctcctcaggg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 2

atgcattctg cccccaagga

20

$\langle 210 \rangle$  3

<211> 4145

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (207) ... (3668)

&lt;400&gt; 3

```

ctgctttaa atctctcggc cacctttgat gaggggactg ggcagttcta gacagtcccg      60

aagttctcaa ggcacaggtc tcttcctggt ttgactgtcc ttaccccgagg gaggcagtgc      120

agccagctgc aagccccaca gtgaagaaca tctgagctca aatccagata agtgacataa      180

gtgacctgct ttgtaaagcc atagag atg gcc tgt cct tgg aaa ttt ctg ttc      233
                Met Ala Cys Pro Trp Lys Phe Leu Phe
                  1                 5

aag acc aaa ttc cac cag tat gca atg aat ggg gaa aaa gac atc aac      281
Lys Thr Lys Phe His Gln Tyr Ala Met Asn Gly Glu Lys Asp Ile Asn
  10                 15                 20                 25

aac aat gtg gag aaa gcc ccc tgt gcc acc tcc agt cca gtg aca cag      329
Asn Asn Val Glu Lys Ala Pro Cys Ala Thr Ser Ser Pro Val Thr Gln
                30                 35                 40

gat gac ctt cag tat cac aac ctc agc aag cag cag aat gag tcc ccg      377
Asp Asp Leu Gln Tyr His Asn Leu Ser Lys Gln Gln Asn Glu Ser Pro
                45                 50                 55

cag ccc ctc gtg gag acg gga aag aag tct cca gaa tct ctg gtc aag      425
Gln Pro Leu Val Glu Thr Gly Lys Lys Ser Pro Glu Ser Leu Val Lys
                60                 65                 70

ctg gat gca acc cca ttg tcc tcc cca cgg cat gtg agg atc aaa aac      473
Leu Asp Ala Thr Pro Leu Ser Ser Pro Arg His Val Arg Ile Lys Asn
                75                 80                 85

tgg ggc agc ggg atg act ttc caa gac aca ctt cac cat aag gcc aaa      521
Trp Gly Ser Gly Met Thr Phe Gln Asp Thr Leu His His Lys Ala Lys
  90                 95                 100                 105

ggg att tta act tgc agg tcc aaa tct tgc ctg ggg tcc att atg act      569
Gly Ile Leu Thr Cys Arg Ser Lys Ser Cys Leu Gly Ser Ile Met Thr
                110                 115                 120

ccc aaa agt ttg acc aga gga ccc agg gac aag cct acc cct cca gat      617
Pro Lys Ser Leu Thr Arg Gly Pro Arg Asp Lys Pro Thr Pro Pro Asp
                125                 130                 135

gag ctt cta cct caa gct atc gaa ttt gtc aac caa tat tac ggc tcc      665

```

Variable	Mean	SD	Min	Max
Age	38.5	12.5	18	65
Gender	0.5	0.5	0	1
Marital status	0.7	0.5	0	1
Education	12.5	2.5	9	16
Income	35000	15000	10000	70000
Health status	0.8	0.4	0	1
Exercise frequency	0.3	0.5	0	1
Stress level	0.6	0.5	0	1
Sleep quality	0.7	0.4	0	1
Work satisfaction	0.5	0.5	0	1
Life satisfaction	0.6	0.5	0	1
Depression score	0.4	0.5	0	1
Anxiety score	0.3	0.4	0	1
Resilience score	0.5	0.5	0	1
Optimism score	0.6	0.5	0	1
Gratitude score	0.7	0.4	0	1
Forgiveness score	0.6	0.5	0	1
Self-compassion score	0.5	0.5	0	1
Emotional regulation score	0.6	0.4	0	1
Prosocial behavior score	0.5	0.5	0	1
Life purpose score	0.6	0.5	0	1
Meaning in life score	0.7	0.4	0	1
Existential well-being score	0.6	0.5	0	1
Overall well-being score	0.6	0.4	0	1

[illegible]

[illegible]

Glu	Asp	Ala	Phe	Arg	Ser	Trp	Ala	Val	Gln	Thr	Phe	Lys	Ala	Ala	Cys				
				670							675							680	
gag	acg	ttt	gat	gtc	cga	ggc	aaa	cag	cac	att	cag	atc	ccc	aag	ctc	2297			
Glu	Thr	Phe	Asp	Val	Arg	Gly	Lys	Gln	His	Ile	Gln	Ile	Pro	Lys	Leu				
				685							690							695	
tac	acc	tcc	aat	gtg	acc	tgg	gac	ccg	cac	cac	tac	agg	ctc	gtg	cag	2345			
Tyr	Thr	Ser	Asn	Val	Thr	Trp	Asp	Pro	His	His	Tyr	Arg	Leu	Val	Gln				
				700							705							710	
gac	tca	cag	cct	ttg	gac	ctc	agc	aaa	gcc	ctc	agc	agc	atg	cat	gcc	2393			
Asp	Ser	Gln	Pro	Leu	Asp	Leu	Ser	Lys	Ala	Leu	Ser	Ser	Met	His	Ala				
				715							720							725	
aag	aac	gtg	ttc	acc	atg	agg	ctc	aaa	tct	cgg	cag	aat	cta	caa	agt	2441			
Lys	Asn	Val	Phe	Thr	Met	Arg	Leu	Lys	Ser	Arg	Gln	Asn	Leu	Gln	Ser				
730							735							740			745		
ccg	aca	tcc	agc	cgt	gcc	acc	atc	ctg	gtg	gaa	ctc	tcc	tgt	gag	gat	2489			
Pro	Thr	Ser	Ser	Arg	Ala	Thr	Ile	Leu	Val	Glu	Leu	Ser	Cys	Glu	Asp				
				750							755							760	
ggc	caa	ggc	ctg	aac	tac	ctg	ccg	ggg	gag	cac	ctt	ggg	gtt	tgc	cca	2537			
Gly	Gln	Gly	Leu	Asn	Tyr	Leu	Pro	Gly	Glu	His	Leu	Gly	Val	Cys	Pro				
				765							770							775	
ggc	aac	cag	ccg	gcc	ctg	gtc	caa	ggc	atc	ctg	gag	cga	gtg	gtg	gat	2585			
Gly	Asn	Gln	Pro	Ala	Leu	Val	Gln	Gly	Ile	Leu	Glu	Arg	Val	Val	Asp				
				780							785							790	
ggc	ccc	aca	ccc	cac	cag	aca	gtg	cgc	ctg	gag	gac	ctg	gat	gag	agt	2633			
Gly	Pro	Thr	Pro	His	Gln	Thr	Val	Arg	Leu	Glu	Asp	Leu	Asp	Glu	Ser				
				795							800							805	
ggc	agc	tac	tgg	gtc	agt	gac	aag	agg	ctg	ccc	ccc	tgc	tca	ctc	agc	2681			
Gly	Ser	Tyr	Trp	Val	Ser	Asp	Lys	Arg	Leu	Pro	Pro	Cys	Ser	Leu	Ser				
810							815							820			825		
cag	gcc	ctc	acc	tac	tcc	ccg	gac	atc	acc	aca	ccc	cca	acc	cag	ctg	2729			
Gln	Ala	Leu	Thr	Tyr	Ser	Pro	Asp	Ile	Thr	Thr	Pro	Pro	Thr	Gln	Leu				
				830							835							840	
ctg	ctc	caa	aag	ctg	gcc	cag	gtg	gcc	aca	gaa	gag	cct	gag	aga	cag	2777			



Leu	Leu	Gln	Lys	Leu	Ala	Gln	Val	Ala	Thr	Glu	Glu	Pro	Glu	Arg	Gln	
			845						850					855		
agg	ctg	gag	gcc	ctg	tgc	cag	ccc	tca	gag	tac	agc	aag	tgg	aag	ttc	2825
Arg	Leu	Glu	Ala	Leu	Cys	Gln	Pro	Ser	Glu	Tyr	Ser	Lys	Trp	Lys	Phe	
			860				865						870			
acc	aac	agc	ccc	aca	ttc	ctg	gag	gtg	cta	gag	gag	ttc	ccg	tcc	ctg	2873
Thr	Asn	Ser	Pro	Thr	Phe	Leu	Glu	Val	Leu	Glu	Glu	Phe	Pro	Ser	Leu	
			875				880					885				
cgg	gtg	tct	gct	ggc	ttc	ctg	ctt	tcc	cag	ctc	ccc	att	ctg	aag	ccc	2921
Arg	Val	Ser	Ala	Gly	Phe	Leu	Leu	Ser	Gln	Leu	Pro	Ile	Leu	Lys	Pro	
890						895					900				905	
agg	ttc	tac	tcc	atc	agc	tcc	tcc	cgg	gat	cac	acg	ccc	acg	gag	atc	2969
Arg	Phe	Tyr	Ser	Ile	Ser	Ser	Ser	Arg	Asp	His	Thr	Pro	Thr	Glu	Ile	
					910					915					920	
cac	ctg	act	gtg	gcc	gtg	gtc	acc	tac	cac	acc	gga	gat	ggc	cag	ggc	3017
His	Leu	Thr	Val	Ala	Val	Val	Thr	Tyr	His	Thr	Gly	Asp	Gly	Gln	Gly	
					925					930					935	
ccc	ctg	cac	cac	ggc	gtc	tgc	agc	aca	tgg	ctc	aac	agc	ctg	aag	ccc	3065
Pro	Leu	His	His	Gly	Val	Cys	Ser	Thr	Trp	Leu	Asn	Ser	Leu	Lys	Pro	
					940					945					950	
caa	gac	cca	gtg	ccc	tgc	ttt	gtg	cgg	aat	gcc	agc	gcc	ttc	cac	ctc	3113
Gln	Asp	Pro	Val	Pro	Cys	Phe	Val	Arg	Asn	Ala	Ser	Ala	Phe	His	Leu	
							960						965			
ccc	gag	gat	ccc	tcc	cat	cct	tgc	atc	ctc	atc	ggg	cct	ggc	aca	ggc	3161
Pro	Glu	Asp	Pro	Ser	His	Pro	Cys	Ile	Leu	Ile	Gly	Pro	Gly	Thr	Gly	
970						975					980				985	
atc	gtg	ccc	ttc	cgc	agt	ttc	tgg	cag	caa	cgg	ctc	cat	gac	tcc	cag	3209
Ile	Val	Pro	Phe	Arg	Ser	Phe	Trp	Gln	Gln	Arg	Leu	His	Asp	Ser	Gln	
					990					995					1000	
cac	aag	gga	gtg	cgg	gga	ggc	cgc	atg	acc	ttg	gtg	ttt	ggg	tgc	cgc	3257
His	Lys	Gly	Val	Arg	Gly	Gly	Arg	Met	Thr	Leu	Val	Phe	Gly	Cys	Arg	
					1005					1010					1015	
cgc	cca	gat	gag	gac	cac	atc	tac	cag	gag	gag	atg	ctg	gag	atg	gcc	3305

[illegible]

gctatcgac cactgtgtat ttaactgcct tgtgtacagt tatttatgcc tctgtattta 4048

aaaaactaac acccagtctg ttcccatgg ccacttgggt cttccctgta tgattccttg 4108

atggagatat ttacatgaat tgcattttac tttaatc 4145

<210> 4

<211> 21

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 4

ggtggaagcg gtaacaaagg a 21

<210> 5

<211> 19

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 5

tgcttgggtgg cgaagatga 19

<210> 6

<211> 30

<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 6

aacaacagga acctaccaac tgacgggaga 30

<210> 7

<211> 19

<212> DNA

g g t g g a a g c g g t a a c a a a g g a

<213> Artificial Sequence

<223> PCR Primer

<400> 7

gaaggtgaag gtcggagtc

19

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 8

gaagatggtg atgggatttc

20

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 9

caagcttccc gttctcagcc

20

<210> 10

<211> 4110

<212> DNA

<213> Mus musculus

<220>

<221> mRNA

<222> (1)...(4110)

<400> 10

ctgctttaaa atctctcggc cacctttgat gaggggactg ggcagttcta gacagtcccg 60

aagttctcaa ggcacaggtc tcttctggt ttgactgtcc ttaccccgagg gaggcagtgc 120

Sequence = Sequence

[illegible]

155	160	165	
aca aag gag ata gaa aca aca gga acc tac caa ctg acg gga gat gag			761
Thr Lys Glu Ile Glu Thr Thr Gly Thr Tyr Gln Leu Thr Gly Asp Glu			
170	175	180	185
ctc atc ttc gcc acc aag cag gcc tgg cgc aat gcc cca cgc tgc att			809
Leu Ile Phe Ala Thr Lys Gln Ala Trp Arg Asn Ala Pro Arg Cys Ile			
190	195	200	
ggg agg atc cag tgg tcc aac ctg cag gtc ttc gat gcc cgc agc tgt			857
Gly Arg Ile Gln Trp Ser Asn Leu Gln Val Phe Asp Ala Arg Ser Cys			
205	210	215	
tcc act gcc cgg gaa atg ttt gaa cac atc tgc aga cac gtg cgt tac			905
Ser Thr Ala Arg Glu Met Phe Glu His Ile Cys Arg His Val Arg Tyr			
220	225	230	
tcc acc aac aat ggc aac atc agg tcg gcc atc acc gtg ttc ccc cag			953
Ser Thr Asn Asn Gly Asn Ile Arg Ser Ala Ile Thr Val Phe Pro Gln			
235	240	245	
cgg agt gat ggc aag cac gac ttc cgg gtg tgg aat gct cag ctc atc			1001
Arg Ser Asp Gly Lys His Asp Phe Arg Val Trp Asn Ala Gln Leu Ile			
250	255	260	265
cgc tat gct ggc tac cag atg cca gat ggc agc atc aga ggg gac cct			1049
Arg Tyr Ala Gly Tyr Gln Met Pro Asp Gly Ser Ile Arg Gly Asp Pro			
270	275	280	
gcc aac gtg gaa ttc act cag ctg tgc atc gac ctg ggc tgg aag ccc			1097
Ala Asn Val Glu Phe Thr Gln Leu Cys Ile Asp Leu Gly Trp Lys Pro			
285	290	295	
aag tac ggc cgc ttc gat gtg gtc ccc ctg gtc ctg cag gcc aat ggc			1145
Lys Tyr Gly Arg Phe Asp Val Val Pro Leu Val Leu Gln Ala Asn Gly			
300	305	310	
cgt gac cct gag ctc ttc gaa atc cca cct gac ctt gtg ctt gag gtg			1193
Arg Asp Pro Glu Leu Phe Glu Ile Pro Pro Asp Leu Val Leu Glu Val			
315	320	325	
gcc atg gaa cat ccc aaa tac gag tgg ttt cgg gaa ctg gag cta aag			1241
Ala Met Glu His Pro Lys Tyr Glu Trp Phe Arg Glu Leu Glu Leu Lys			

RTS-0066

330											335											340											345										
tgg tac gcc ctg cct gca gtg gcc aac atg ctg ctt gag gtg ggc ggc											1289																																
Trp Tyr Ala Leu Pro Ala Val Ala Asn Met Leu Leu Glu Val Gly Gly											1290																																
350										355										360																							
ctg gag ttc cca ggg tgc ccc ttc aat ggc tgg tac atg ggc aca gag											1337																																
Leu Glu Phe Pro Gly Cys Pro Phe Asn Gly Trp Tyr Met Gly Thr Glu											1338																																
365										370										375																							
atc gga gtc cgg gac ttc tgt gac gtc cag cgc tac aac atc ctg gag											1385																																
Ile Gly Val Arg Asp Phe Cys Asp Val Gln Arg Tyr Asn Ile Leu Glu											1386																																
380										385										390																							
gaa gtg ggc agg aga atg ggc ctg gaa acg cac aag ctg gcc tcg ctc											1433																																
Glu Val Gly Arg Arg Met Gly Leu Glu Thr His Lys Leu Ala Ser Leu											1434																																
395										400										405																							
tgg aaa gac cag gct gtc gtt gag atc aac att gct gtg atc cat agt											1481																																
Trp Lys Asp Gln Ala Val Val Glu Ile Asn Ile Ala Val Ile His Ser											1482																																
410	415										420										425																						
ttt cag aag cag aat gtg acc atc atg gac cac cac tcg gct gca gaa											1529																																
Phe Gln Lys Gln Asn Val Thr Ile Met Asp His His Ser Ala Ala Glu											1530																																
430										435										440																							
tcc ttc atg aag tac atg cag aat gaa tac cgg tcc cgt ggg ggc tgc											1577																																
Ser Phe Met Lys Tyr Met Gln Asn Glu Tyr Arg Ser Arg Gly Gly Cys											1578																																
445										450										455																							
ccg gca gac tgg att tgg ctg gtc cct ccc atg tct ggg agc atc acc											1625																																
Pro Ala Asp Trp Ile Trp Leu Val Pro Pro Met Ser Gly Ser Ile Thr											1626																																
460										465										470																							
ccc gtg ttt cac cag gag atg ctg aac tac gtc ctg tcc cct ttc tac											1673																																
Pro Val Phe His Gln Glu Met Leu Asn Tyr Val Leu Ser Pro Phe Tyr											1674																																
475										480										485																							
tac tat cag gta gag gcc tgg aaa acc cat gtc tgg cag gac gag aag											1721																																
Tyr Tyr Gln Val Glu Ala Trp Lys Thr His Val Trp Gln Asp Glu Lys											1722																																
490										495										500										505													
cgg aga ccc aag aga aga gag att cca ttg aaa gtc ttg gtc aaa gct											1769																																
Arg Arg Pro Lys Arg Arg Glu Ile Pro Leu Lys Val Leu Val Lys Ala											1770																																

510								515					520					
gtg	ctc	ttt	gcc	tgt	atg	ctg	atg	cgc	aag	aca	atg	gcg	tcc	cga	gtc	1817		
Val	Leu	Phe	Ala	Cys	Met	Leu	Met	Arg	Lys	Thr	Met	Ala	Ser	Arg	Val			
			525						530			535						
aga	gtc	acc	atc	ctc	ttt	gcg	aca	gag	aca	gga	aaa	tca	gag	gcg	ctg	1865		
Arg	Val	Thr	Ile	Leu	Phe	Ala	Thr	Glu	Thr	Gly	Lys	Ser	Glu	Ala	Leu			
			540						545			550						
gcc	tgg	gac	ctg	ggg	gcc	tta	ttc	agc	tgt	gcc	ttc	aac	ccc	aag	gtt	1913		
Ala	Trp	Asp	Leu	Gly	Ala	Leu	Phe	Ser	Cys	Ala	Phe	Asn	Pro	Lys	Val			
			555						560			565						
gtc	tgc	atg	gat	aag	tac	agg	ctg	agc	tgc	ctg	gag	gag	gaa	cgg	ctg	1961		
Val	Cys	Met	Asp	Lys	Tyr	Arg	Leu	Ser	Cys	Leu	Glu	Glu	Glu	Arg	Leu			
570						575						580			585			
ctg	ttg	gtg	gtg	acc	agt	acg	ttt	ggc	aat	gga	gac	tgc	cct	ggc	aat	2009		
Leu	Leu	Val	Val	Thr	Ser	Thr	Phe	Gly	Asn	Gly	Asp	Cys	Pro	Gly	Asn			
			590						595			600						
gga	gag	aaa	ctg	aag	aaa	tcg	ctc	ttc	atg	ctg	aaa	gag	ctc	aac	aac	2057		
Gly	Glu	Lys	Leu	Lys	Lys	Ser	Leu	Phe	Met	Leu	Lys	Glu	Leu	Asn	Asn			
			605						610			615						
aaa	ttc	agg	tac	gct	gtg	ttt	ggc	ctc	ggc	tcc	agc	atg	tac	cct	cgg	2105		
Lys	Phe	Arg	Tyr	Ala	Val	Phe	Gly	Leu	Gly	Ser	Ser	Met	Tyr	Pro	Arg			
			620						625			630						
ttc	tgc	gcc	ttt	gct	cat	gac	att	gat	cag	aag	ctg	tcc	cac	ctg	ggg	2153		
Phe	Cys	Ala	Phe	Ala	His	Asp	Ile	Asp	Gln	Lys	Leu	Ser	His	Leu	Gly			
635						640						645						
gcc	tct	cag	ctc	acc	ccg	atg	gga	gaa	ggg	gat	gag	ctc	agt	ggg	cag	2201		
Ala	Ser	Gln	Leu	Thr	Pro	Met	Gly	Glu	Gly	Asp	Glu	Leu	Ser	Gly	Gln			
650						655						660			665			
gag	gac	gcc	ttc	cgc	agc	tgg	gcc	gtg	caa	acc	ttc	aag	gca	gcc	tgt	2249		
Glu	Asp	Ala	Phe	Arg	Ser	Trp	Ala	Val	Gln	Thr	Phe	Lys	Ala	Ala	Cys			
			670						675			680						
gag	acg	ttt	gat	gtc	cga	ggc	aaa	cag	cac	att	cag	atc	ccc	aag	ctc	2297		
Glu	Thr	Phe	Asp	Val	Arg	Gly	Lys	Gln	His	Ile	Gln	Ile	Pro	Lys	Leu			



	685					690					695					
tac acc tcc aat gtg acc tgg gac ccg cac cac tac agg ctc gtg cag																2345
Tyr Thr Ser Asn Val Thr Trp Asp Pro His His Tyr Arg Leu Val Gln																
	700					705					710					
gac tca cag cct ttg gac ctc agc aaa gcc ctc agc agc atg cat gcc																2393
Asp Ser Gln Pro Leu Asp Leu Ser Lys Ala Leu Ser Ser Met His Ala																
	715					720					725					
aag aac gtg ttc acc atg agg ctc aaa tct cgg cag aat cta caa agt																2441
Lys Asn Val Phe Thr Met Arg Leu Lys Ser Arg Gln Asn Leu Gln Ser																
730	735					740					745					
ccg aca tcc agc cgt gcc acc atc ctg gtg gaa ctc tcc tgt gag gat																2489
Pro Thr Ser Ser Arg Ala Thr Ile Leu Val Glu Leu Ser Cys Glu Asp																
	750					755					760					
ggc caa ggc ctg aac tac ctg ccg ggg gag cac ctt ggg gtt tgc cca																2537
Gly Gln Gly Leu Asn Tyr Leu Pro Gly Glu His Leu Gly Val Cys Pro																
	765					770					775					
ggc aac cag ccg gcc ctg gtc caa ggc atc ctg gag cga gtg gtg gat																2585
Gly Asn Gln Pro Ala Leu Val Gln Gly Ile Leu Glu Arg Val Val Asp																
	780					785					790					
ggc ccc aca ccc cac cag aca gtg cgc ctg gag gac ctg gat gag agt																2633
Gly Pro Thr Pro His Gln Thr Val Arg Leu Glu Asp Leu Asp Glu Ser																
	795					800					805					
ggc agc tac tgg gtc agt gac aag agg ctg ccc ccc tgc tca ctc agc																2681
Gly Ser Tyr Trp Val Ser Asp Lys Arg Leu Pro Pro Cys Ser Leu Ser																
810	815					820					825					
cag gcc ctc acc tac tcc ccg gac atc acc aca ccc cca acc cag ctg																2729
Gln Ala Leu Thr Tyr Ser Pro Asp Ile Thr Thr Pro Pro Thr Gln Leu																
	830					835					840					
ctg ctc caa aag ctg gcc cag gtg gcc aca gaa gag cct gag aga cag																2777
Leu Leu Gln Lys Leu Ala Gln Val Ala Thr Glu Glu Pro Glu Arg Gln																
	845					850					855					
agg ctg gag gcc ctg tgc cag ccc tca gag tac agc aag tgg aag ttc																2825
Arg Leu Glu Ala Leu Cys Gln Pro Ser Glu Tyr Ser Lys Trp Lys Phe																

860	865	870	
acc aac agc ccc aca ttc ctg gag gtg cta gag gag ttc ccg tcc ctg			2873
Thr Asn Ser Pro Thr Phe Leu Glu Val Leu Glu Glu Phe Pro Ser Leu			
875	880	885	
cgg gtg tct gct ggc ttc ctg ctt tcc cag ctc ccc att ctg aag ccc			2921
Arg Val Ser Ala Gly Phe Leu Leu Ser Gln Leu Pro Ile Leu Lys Pro			
890	895	900	905
agg ttc tac tcc atc agc tcc tcc cgg gat cac acg ccc acg gag atc			2969
Arg Phe Tyr Ser Ile Ser Ser Ser Arg Asp His Thr Pro Thr Glu Ile			
	910	915	920
cac ctg act gtg gcc gtg gtc acc tac cac acc gga gat ggc cag ggt			3017
His Leu Thr Val Ala Val Val Thr Tyr His Thr Gly Asp Gly Gln Gly			
	925	930	935
ccc ctg cac cac ggt gtc tgc agc aca tgg ctc aac agc ctg aag ccc			3065
Pro Leu His His Gly Val Cys Ser Thr Trp Leu Asn Ser Leu Lys Pro			
	940	945	950
caa gac cca gtg ccc tgc ttt gtg cgg aat gcc agc gcc ttc cac ctc			3113
Gln Asp Pro Val Pro Cys Phe Val Arg Asn Ala Ser Ala Phe His Leu			
	955	960	965
ccc gag gat ccc tcc cat cct tgc atc ctc atc ggg cct ggc aca ggc			3161
Pro Glu Asp Pro Ser His Pro Cys Ile Leu Ile Gly Pro Gly Thr Gly			
970	975	980	985
atc gtg ccc ttc cgc agt ttc tgg cag caa cgg ctc cat gac tcc cag			3209
Ile Val Pro Phe Arg Ser Phe Trp Gln Gln Arg Leu His Asp Ser Gln			
	990	995	1000
cac aag gga gtg cgg gga ggc cgc atg acc ttg gtg ttt ggg tgc cgc			3257
His Lys Gly Val Arg Gly Gly Arg Met Thr Leu Val Phe Gly Cys Arg			
	1005	1010	1015
cgc cca gat gag gac cac atc tac cag gag gag atg ctg gag atg gcc			3305
Arg Pro Asp Glu Asp His Ile Tyr Gln Glu Glu Met Leu Glu Met Ala			
	1020	1025	1030
cag aag ggg gtg ctg cat gcg gtg cac aca gcc tat tcc cgc ctg cct			3353
Gln Lys Gly Val Leu His Ala Val His Thr Ala Tyr Ser Arg Leu Pro			

1035	1040	1045	
ggc aag ccc aag gtc tat gtt cag gac atc ctg cgg cag cag ctg gcc			3401
Gly Lys Pro Lys Val Tyr Val Gln Asp Ile Leu Arg Gln Gln Leu Ala			
1050	1055	1060	1065
agc gag gtg ctc cgt gtg ctc cac aag gag cca ggc cac ctc tat gtt			3449
Ser Glu Val Leu Arg Val Leu His Lys Glu Pro Gly His Leu Tyr Val			
	1070	1075	1080
tgc ggg gat gtg cgc atg gcc cgg gac gtg gcc cac acc ctg aag cag			3497
Cys Gly Asp Val Arg Met Ala Arg Asp Val Ala His Thr Leu Lys Gln			
	1085	1090	1095
ctg gtg gct gcc aag ctg aaa ttg aat gag gag cag gtc gag gac tat			3545
Leu Val Ala Ala Lys Leu Lys Leu Asn Glu Glu Gln Val Glu Asp Tyr			
	1100	1105	1110
ttc ttt cag ctc aag agc cag aag cgc tat cac gaa gat atc ttc ggt			3593
Phe Phe Gln Leu Lys Ser Gln Lys Arg Tyr His Glu Asp Ile Phe Gly			
	1115	1120	1125
gct gta ttt cct tac gag gcg aag aag gac agg gtg gcg gtg cag ccc			3641
Ala Val Phe Pro Tyr Glu Ala Lys Lys Asp Arg Val Ala Val Gln Pro			
1130	1135	1140	1145
agc agc ctg gag atg tca gcg ctc tga gggcctacag gaggggttaa			3688
Ser Ser Leu Glu Met Ser Ala Leu			
	1150		
agctgccggc acagaactta aggatggagc cagctctgca ttatctgagg tcacagggcc			3748
tggggagatg gaggaaagtg atatcccca gcctcaagtc ttatttcctc aacgttgctc			3808
cccatcaagc cctttacttg acctcctaac aagtagcacc ctggattgat cggagcctcc			3868
tctctcaaac tggggcctcc ctgggtccctt ggagacaaaa tcttaaatgc caggcctggc			3928
gagtgggtga aagatggaac ttgctgctga gtgcaccact tcaagtgacc accaggaggt			3988
gctatcgcac cactgtgtat ttaactgcct tgtgtacagt tatttatgcc tctgtattta			4048
aaaaactaac acccagtctg ttccccatgg ccacttgggt cttccctgta tgattccttg			4108

atggagatat ttacatgaat tgcattttac tttaatc

4145

<210> 11

<211> 23

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 11

cgtccacagt atgtgaggat caa

23

<210> 12

<211> 22

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 12

caagcaagac ttggacttgc aa

22

<210> 13

<211> 26

<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 13

tcttcaccac aaggccacat cggatt

26

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 14

atgagatat ttacatgaat tgcattttac tttaatc

ggcaaattca acggcacagt

20

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 15

gggtctcgct cctggaagct

20

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 16

aaggccgaga atgggaagct tgtcatc

27

<210> 17

<211> 5484

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (34)...(3960)

<400> 17

aattgtcagc acgggatctg agacttccaa aaa atg aag ccg gcg aca gga ctt 54

Met Lys Pro Ala Thr Gly Leu

1

5

tgg gtc tgg gtg agc ctt ctc gtg gcg gcg ggg acc gtc cag ccc agc 102

Trp Val Trp Val Ser Leu Leu Val Ala Ala Gly Thr Val Gln Pro Ser

10

15

20

gat tct cag tca gtg tgt gca gga acg gag aat aaa ctg agc tct ctc 150

U.S. Pat. & Tm. Off.

Asp Ser Gln Ser Val Cys Ala Gly Thr Glu Asn Lys Leu Ser Ser Leu  
 25 30 35

tct gac ctg gaa cag cag tac cga gcc ttg cgc aag tac tat gaa aac 198  
 Ser Asp Leu Glu Gln Gln Tyr Arg Ala Leu Arg Lys Tyr Tyr Glu Asn  
 40 45 50 55

tgt gag gtt gtc atg ggc aac ctg gag ata acc agc att gag cac aac 246  
 Cys Glu Val Val Met Gly Asn Leu Glu Ile Thr Ser Ile Glu His Asn  
 60 65 70

cgg gac ctc tcc ttc ctg cgg tct gtt cga gaa gtc aca ggc tac gtg 294  
 Arg Asp Leu Ser Phe Leu Arg Ser Val Arg Glu Val Thr Gly Tyr Val  
 75 80 85

tta gtg gct ctt aat cag ttt cgt tac ctg cct ctg gag aat tta cgc 342  
 Leu Val Ala Leu Asn Gln Phe Arg Tyr Leu Pro Leu Glu Asn Leu Arg  
 90 95 100

att att cgt ggg aca aaa ctt tat gag gat cga tat gcc ttg gca ata 390  
 Ile Ile Arg Gly Thr Lys Leu Tyr Glu Asp Arg Tyr Ala Leu Ala Ile  
 105 110 115

ttt tta aac tac aga aaa gat gga aac ttt gga ctt caa gaa ctt gga 438  
 Phe Leu Asn Tyr Arg Lys Asp Gly Asn Phe Gly Leu Gln Glu Leu Gly  
 120 125 130 135

tta aag aac ttg aca gaa atc cta aat ggt gga gtc tat gta gac cag 486  
 Leu Lys Asn Leu Thr Glu Ile Leu Asn Gly Gly Val Tyr Val Asp Gln  
 140 145 150

aac aaa ttc ctt tgt tat gca gac acc att cat tgg caa gat att gtt 534  
 Asn Lys Phe Leu Cys Tyr Ala Asp Thr Ile His Trp Gln Asp Ile Val  
 155 160 165

cgg aac cca tgg cct tcc aac ttg act ctt gtg tca aca aat ggt agt 582  
 Arg Asn Pro Trp Pro Ser Asn Leu Thr Leu Val Ser Thr Asn Gly Ser  
 170 175 180

tca gga tgt gga cgt tgc cat aag tcc tgt act ggc cgt tgc tgg gga 630  
 Ser Gly Cys Gly Arg Cys His Lys Ser Cys Thr Gly Arg Cys Trp Gly  
 185 190 195

ccc aca gaa aat cat tgc cag act ttg aca agg acg gtg tgt gca gaa 678

Pro	Thr	Glu	Asn	His	Cys	Gln	Thr	Leu	Thr	Arg	Thr	Val	Cys	Ala	Glu	
200					205					210					215	
caa	tgt	gac	ggc	aga	tgc	tac	gga	cct	tac	gtc	agt	gac	tgc	tgc	cat	726
Gln	Cys	Asp	Gly	Arg	Cys	Tyr	Gly	Pro	Tyr	Val	Ser	Asp	Cys	Cys	His	
				220					225					230		
cga	gaa	tgt	gct	gga	ggc	tgc	tca	gga	cct	aag	gac	aca	gac	tgc	ttt	774
Arg	Glu	Cys	Ala	Gly	Gly	Cys	Ser	Gly	Pro	Lys	Asp	Thr	Asp	Cys	Phe	
			235					240					245			
gcc	tgc	atg	aat	ttc	aat	gac	agt	gga	gca	tgt	gtt	act	cag	tgt	ccc	822
Ala	Cys	Met	Asn	Phe	Asn	Asp	Ser	Gly	Ala	Cys	Val	Thr	Gln	Cys	Pro	
		250					255					260				
caa	acc	ttt	gtc	tac	aat	cca	acc	acc	ttt	caa	ctg	gag	cac	aat	ttc	870
Gln	Thr	Phe	Val	Tyr	Asn	Pro	Thr	Thr	Phe	Gln	Leu	Glu	His	Asn	Phe	
	265					270				275						
aat	gca	aag	tac	aca	tat	gga	gca	ttc	tgt	gtc	aag	aaa	tgt	cca	cat	918
Asn	Ala	Lys	Tyr	Thr	Tyr	Gly	Ala	Phe	Cys	Val	Lys	Lys	Cys	Pro	His	
280					285				290					295		
aac	ttt	gtg	gta	gat	tcc	agt	tct	tgt	gtg	cgt	gcc	tgc	cct	agt	tcc	966
Asn	Phe	Val	Val	Asp	Ser	Ser	Ser	Cys	Val	Arg	Ala	Cys	Pro	Ser	Ser	
			300					305					310			
aag	atg	gaa	gta	gaa	gaa	aat	ggg	att	aaa	atg	tgt	aaa	cct	tgc	act	1014
Lys	Met	Glu	Val	Glu	Glu	Asn	Gly	Ile	Lys	Met	Cys	Lys	Pro	Cys	Thr	
		315					320					325				
gac	att	tgc	cca	aaa	gct	tgt	gat	ggc	att	ggc	aca	gga	tca	ttg	atg	1062
Asp	Ile	Cys	Pro	Lys	Ala	Cys	Asp	Gly	Ile	Gly	Thr	Gly	Ser	Leu	Met	
		330					335					340				
tca	gct	cag	act	gtg	gat	tcc	agt	aac	att	gac	aaa	ttc	ata	aac	tgt	1110
Ser	Ala	Gln	Thr	Val	Asp	Ser	Ser	Asn	Ile	Asp	Lys	Phe	Ile	Asn	Cys	
	345					350				355						
acc	aag	atc	aat	ggg	aat	ttg	atc	ttt	cta	gtc	act	ggt	att	cat	ggg	1158
Thr	Lys	Ile	Asn	Gly	Asn	Leu	Ile	Phe	Leu	Val	Thr	Gly	Ile	His	Gly	
360				365				370						375		
gac	cct	tac	aat	gca	att	gaa	gcc	ata	gac	cca	gag	aaa	ctg	aac	gtc	1206

Asp	Pro	Tyr	Asn	Ala	Ile	Glu	Ala	Ile	Asp	Pro	Glu	Lys	Leu	Asn	Val	
				380				385				390				
ttt	cgg	aca	gtc	aga	gag	ata	aca	ggc	ttc	ctg	aac	ata	cag	tca	tgg	1254
Phe	Arg	Thr	Val	Arg	Glu	Ile	Thr	Gly	Phe	Leu	Asn	Ile	Gln	Ser	Trp	
				395				400				405				
cca	cca	aac	atg	act	gac	ttc	agt	gtt	ttt	tct	aac	ctg	gtg	acc	att	1302
Pro	Pro	Asn	Met	Thr	Asp	Phe	Ser	Val	Phe	Ser	Asn	Leu	Val	Thr	Ile	
				410				415				420				
ggc	gga	aga	gta	ctc	tat	agt	ggc	ctg	tcc	ttg	ctt	atc	ctc	aag	caa	1350
Gly	Gly	Arg	Val	Leu	Tyr	Ser	Gly	Leu	Ser	Leu	Leu	Ile	Leu	Lys	Gln	
				425				430				435				
cag	ggc	atc	acc	tct	cta	cag	ttc	cag	tcc	ctg	aag	gaa	atc	agc	gca	1398
Gln	Gly	Ile	Thr	Ser	Leu	Gln	Phe	Gln	Ser	Leu	Lys	Glu	Ile	Ser	Ala	
440				445				450				455				
gga	aac	atc	tat	att	act	gac	aac	agc	aac	ctg	tgt	tat	tat	cat	acc	1446
Gly	Asn	Ile	Tyr	Ile	Thr	Asp	Asn	Ser	Asn	Leu	Cys	Tyr	Tyr	His	Thr	
				460				465				470				
att	aac	tgg	aca	aca	ctc	ttc	agc	aca	atc	aac	cag	aga	ata	gta	atc	1494
Ile	Asn	Trp	Thr	Thr	Leu	Phe	Ser	Thr	Ile	Asn	Gln	Arg	Ile	Val	Ile	
				475				480				485				
cgg	gac	aac	aga	aaa	gct	gaa	aat	tgt	act	gct	gaa	gga	atg	gtg	tgc	1542
Arg	Asp	Asn	Arg	Lys	Ala	Glu	Asn	Cys	Thr	Ala	Glu	Gly	Met	Val	Cys	
				490				495				500				
aac	cat	ctg	tgt	tcc	agt	gat	ggc	tgt	tgg	gga	cct	ggg	cca	gac	caa	1590
Asn	His	Leu	Cys	Ser	Ser	Asp	Gly	Cys	Trp	Gly	Pro	Gly	Pro	Asp	Gln	
				505				510				515				
tgt	ctg	tgc	tgt	cgc	cgc	ttc	agt	aga	gga	agg	atc	tgc	ata	gag	tct	1638
Cys	Leu	Ser	Cys	Arg	Arg	Phe	Ser	Arg	Gly	Arg	Ile	Cys	Ile	Glu	Ser	
520				525				530				535				
tgt	aac	ctc	tat	gat	ggc	gaa	ttt	cgg	gag	ttt	gag	aat	ggc	tcc	atc	1686
Cys	Asn	Leu	Tyr	Asp	Gly	Glu	Phe	Arg	Glu	Phe	Glu	Asn	Gly	Ser	Ile	
				540				545				550				
tgt	gtg	gag	tgt	gac	ccc	cag	tgt	gag	aag	atg	gaa	gat	ggc	ctc	ctc	1734



Cys	Val	Glu	Cys	Asp	Pro	Gln	Cys	Glu	Lys	Met	Glu	Asp	Gly	Leu	Leu	
555						560						565				
aca	tgc	cat	gga	ccg	ggt	cct	gac	aac	tgt	aca	aag	tgc	tct	cat	ttt	1782
Thr	Cys	His	Gly	Pro	Gly	Pro	Asp	Asn	Cys	Thr	Lys	Cys	Ser	His	Phe	
570						575						580				
aaa	gat	ggc	cca	aac	tgt	gtg	gaa	aaa	tgt	cca	gat	ggc	tta	cag	ggg	1830
Lys	Asp	Gly	Pro	Asn	Cys	Val	Glu	Lys	Cys	Pro	Asp	Gly	Leu	Gln	Gly	
585						590						595				
gca	aac	agt	ttc	att	ttc	aag	tat	gct	gat	cca	gat	cgg	gag	tgc	cac	1878
Ala	Asn	Ser	Phe	Ile	Phe	Lys	Tyr	Ala	Asp	Pro	Asp	Arg	Glu	Cys	His	
600						605						610			615	
cca	tgc	cat	cca	aac	tgc	acc	caa	ggg	tgt	aac	ggt	ccc	act	agt	cat	1926
Pro	Cys	His	Pro	Asn	Cys	Thr	Gln	Gly	Cys	Asn	Gly	Pro	Thr	Ser	His	
			620						625						630	
gac	tgc	att	tac	tac	cca	tgg	acg	ggc	cat	tcc	act	tta	cca	caa	cat	1974
Asp	Cys	Ile	Tyr	Tyr	Pro	Trp	Thr	Gly	His	Ser	Thr	Leu	Pro	Gln	His	
			635						640						645	
gct	aga	act	ccc	ctg	att	gca	gct	gga	gta	att	ggt	ggg	ctc	ttc	att	2022
Ala	Arg	Thr	Pro	Leu	Ile	Ala	Ala	Gly	Val	Ile	Gly	Gly	Leu	Phe	Ile	
650						655						660				
ctg	gtc	att	gtg	ggt	ctg	aca	ttt	gct	gtt	tat	gtt	aga	agg	aag	agc	2070
Leu	Val	Ile	Val	Gly	Leu	Thr	Phe	Ala	Val	Tyr	Val	Arg	Arg	Lys	Ser	
665						670						675				
atc	aaa	aag	aaa	aga	gcc	ttg	aga	aga	ttc	ttg	gaa	aca	gag	ttg	gtg	2118
Ile	Lys	Lys	Lys	Arg	Ala	Leu	Arg	Arg	Phe	Leu	Glu	Thr	Glu	Leu	Val	
680						685						690			695	
gaa	cca	tta	act	ccc	agt	ggc	aca	gca	ccc	aat	caa	gct	caa	ctt	cgt	2166
Glu	Pro	Leu	Thr	Pro	Ser	Gly	Thr	Ala	Pro	Asn	Gln	Ala	Gln	Leu	Arg	
			700						705						710	
att	ttg	aaa	gaa	act	gag	ctg	aag	agg	gta	aaa	gtc	ctt	ggc	tca	ggt	2214
Ile	Leu	Lys	Glu	Thr	Glu	Leu	Lys	Arg	Val	Lys	Val	Leu	Gly	Ser	Gly	
			715						720						725	
gct	ttt	gga	acg	gtt	tat	aaa	ggt	att	tgg	gta	cct	gaa	gga	gaa	act	2262

Ala Phe Gly Thr Val Tyr Lys Gly Ile Trp Val Pro Glu Gly Glu Thr  
730 735 740

gtg aag att cct gtg gct att aag att ctt aat gag aca act ggt ccc 2310  
Val Lys Ile Pro Val Ala Ile Lys Ile Leu Asn Glu Thr Thr Gly Pro  
745 750 755

aag gca aat gtg gag ttc atg gat gaa gct ctg atc atg gca agt atg 2358  
Lys Ala Asn Val Glu Phe Met Asp Glu Ala Leu Ile Met Ala Ser Met  
760 765 770 775

gat cat cca cac cta gtc cgg ttg ctg ggt gtg tgt ctg agc cca acc 2406  
Asp His Pro His Leu Val Arg Leu Leu Gly Val Cys Leu Ser Pro Thr  
780 785 790

atc cag ctg gtt act caa ctt atg ccc cat ggc tgc ctg ttg gag tat 2454  
Ile Gln Leu Val Thr Gln Leu Met Pro His Gly Cys Leu Leu Glu Tyr  
795 800 805

gtc cac gag cac aag gat aac att gga tca caa ctg ctg ctt aac tgg 2502  
Val His Glu His Lys Asp Asn Ile Gly Ser Gln Leu Leu Leu Asn Trp  
810 815 820

tgt gtc cag ata gct aag gga atg atg tac ctg gaa gaa aga cga ctc 2550  
Cys Val Gln Ile Ala Lys Gly Met Met Tyr Leu Glu Glu Arg Arg Leu  
825 830 835

gtt cat cgg gat ttg gca gcc cgt aat gtc tta gtg aaa tct cca aac 2598  
Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Lys Ser Pro Asn  
840 845 850 855

cat gtg aaa atc aca gat ttt ggg cta gcc aga ctc ttg gaa gga gat 2646  
His Val Lys Ile Thr Asp Phe Gly Leu Ala Arg Leu Leu Glu Gly Asp  
860 865 870

gaa aaa gag tac aat gct gat gga gga aag atg cca att aaa tgg atg 2694  
Glu Lys Glu Tyr Asn Ala Asp Gly Gly Lys Met Pro Ile Lys Trp Met  
875 880 885

gct ctg gag tgt ata cat tac agg aaa ttc acc cat cag agt gac gtt 2742  
Ala Leu Glu Cys Ile His Tyr Arg Lys Phe Thr His Gln Ser Asp Val  
890 895 900

tgg agc tat gga gtt act ata tgg gaa ctg atg acc ttt gga gga aaa 2790

Trp	Ser	Tyr	Gly	Val	Thr	Ile	Trp	Glu	Leu	Met	Thr	Phe	Gly	Gly	Lys	
905							910					915				
ccc	tat	gat	gga	att	cca	acg	cga	gaa	atc	cct	gat	tta	tta	gag	aaa	2838
Pro	Tyr	Asp	Gly	Ile	Pro	Thr	Arg	Glu	Ile	Pro	Asp	Leu	Leu	Glu	Lys	
920					925					930					935	
gga	gaa	cgt	ttg	cct	cag	cct	ccc	atc	tgc	act	att	gac	gtt	tac	atg	2886
Gly	Glu	Arg	Leu	Pro	Gln	Pro	Pro	Ile	Cys	Thr	Ile	Asp	Val	Tyr	Met	
				940					945					950		
gtc	atg	gtc	aaa	tgt	tgg	atg	att	gat	gct	gac	agt	aga	cct	aaa	ttt	2934
Val	Met	Val	Lys	Cys	Trp	Met	Ile	Asp	Ala	Asp	Ser	Arg	Pro	Lys	Phe	
			955					960					965			
aag	gaa	ctg	gct	gct	gag	ttt	tca	agg	atg	gct	cga	gac	cct	caa	aga	2982
Lys	Glu	Leu	Ala	Ala	Glu	Phe	Ser	Arg	Met	Ala	Arg	Asp	Pro	Gln	Arg	
		970					975					980				
tac	cta	gtt	att	cag	ggg	gat	gat	cgt	atg	aag	ctt	ccc	agt	cca	aat	3030
Tyr	Leu	Val	Ile	Gln	Gly	Asp	Asp	Arg	Met	Lys	Leu	Pro	Ser	Pro	Asn	
	985					990					995					
gac	agc	aag	ttc	ttt	cag	aat	ctc	ttg	gat	gaa	gag	gat	ttg	gaa	gat	3078
Asp	Ser	Lys	Phe	Phe	Gln	Asn	Leu	Leu	Asp	Glu	Glu	Asp	Leu	Glu	Asp	
1000					1005					1010					1015	
atg	atg	gat	gct	gag	gag	tac	ttg	gtc	cct	cag	gct	ttc	aac	atc	cca	3126
Met	Met	Asp	Ala	Glu	Glu	Tyr	Leu	Val	Pro	Gln	Ala	Phe	Asn	Ile	Pro	
				1020					1025				1030			
cct	ccc	atc	tat	act	tcc	aga	gca	aga	att	gac	tcg	aat	agg	agt	gaa	3174
Pro	Pro	Ile	Tyr	Thr	Ser	Arg	Ala	Arg	Ile	Asp	Ser	Asn	Arg	Ser	Glu	
			1035					1040					1045			
att	gga	cac	agc	cct	cct	cct	gcc	tac	acc	ccc	atg	tca	gga	aac	cag	3222
Ile	Gly	His	Ser	Pro	Pro	Pro	Ala	Tyr	Thr	Pro	Met	Ser	Gly	Asn	Gln	
		1050					1055					1060				
ttt	gta	tac	cga	gat	gga	ggg	ttt	gct	gct	gaa	caa	gga	gtg	tct	gtg	3270
Phe	Val	Tyr	Arg	Asp	Gly	Gly	Phe	Ala	Ala	Glu	Gln	Gly	Val	Ser	Val	
	1065					1070				1075						
ccc	tac	aga	gcc	cca	act	agc	aca	att	cca	gaa	gct	cct	gtg	gca	cag	3318

Pro Tyr Arg Ala Pro Thr Ser Thr Ile Pro Glu Ala Pro Val Ala Gln  
1080 1085 1090 1095

ggt gct act gct gag att ttt gat gac tcc tgc tgt aat ggc acc cta 3366  
Gly Ala Thr Ala Glu Ile Phe Asp Asp Ser Cys Cys Asn Gly Thr Leu  
1100 1105 1110

cgc aag cca gtg gca ccc cat gtc caa gag gac agt agc acc cag agg 3414  
Arg Lys Pro Val Ala Pro His Val Gln Glu Asp Ser Ser Thr Gln Arg  
1115 1120 1125

tac agt gct gac ccc acc gtg ttt gcc cca gaa cgg agc cca cga gga 3462  
Tyr Ser Ala Asp Pro Thr Val Phe Ala Pro Glu Arg Ser Pro Arg Gly  
1130 1135 1140

gag ctg gat gag gaa ggt tac atg act cct atg cga gac aaa ccc aaa 3510  
Glu Leu Asp Glu Glu Gly Tyr Met Thr Pro Met Arg Asp Lys Pro Lys  
1145 1150 1155

caa gaa tac ctg aat cca gtg gag gag aac cct ttt gtt tct cgg aga 3558  
Gln Glu Tyr Leu Asn Pro Val Glu Glu Asn Pro Phe Val Ser Arg Arg  
1160 1165 1170 1175

aaa aat gga gac ctt caa gca ttg gat aat ccc gaa tat cac aat gca 3606  
Lys Asn Gly Asp Leu Gln Ala Leu Asp Asn Pro Glu Tyr His Asn Ala  
1180 1185 1190

tcc aat ggt cca ccc aag gcc gag gat gag tat gtg aat gag cca ctg 3654  
Ser Asn Gly Pro Pro Lys Ala Glu Asp Glu Tyr Val Asn Glu Pro Leu  
1195 1200 1205

tac ctc aac acc ttt gcc aac acc ttg gga aaa gct gag tac ctg aag 3702  
Tyr Leu Asn Thr Phe Ala Asn Thr Leu Gly Lys Ala Glu Tyr Leu Lys  
1210 1215 1220

aac aac ata ctg tca atg cca gag aag gcc aag aaa gcg ttt gac aac 3750  
Asn Asn Ile Leu Ser Met Pro Glu Lys Ala Lys Lys Ala Phe Asp Asn  
1225 1230 1235

cct gac tac tgg aac cac agc ctg cca cct cgg agc acc ctt cag cac 3798  
Pro Asp Tyr Trp Asn His Ser Leu Pro Pro Arg Ser Thr Leu Gln His  
1240 1245 1250 1255

cca gac tac ctg cag gag tac agc aca aaa tat ttt tat aaa cag aat 3846

Pro Asp Tyr Leu Gln Glu Tyr Ser Thr Lys Tyr Phe Tyr Lys Gln Asn  
 1260 1265 1270

ggg cgg atc cgg cct att gtg gca gag aat cct gaa tac ctc tct gag 3894  
 Gly Arg Ile Arg Pro Ile Val Ala Glu Asn Pro Glu Tyr Leu Ser Glu  
 1275 1280 1285

ttc tcc ctg aag cca ggc act gtg ctg ccg cct cca cct tac aga cac 3942  
 Phe Ser Leu Lys Pro Gly Thr Val Leu Pro Pro Pro Pro Tyr Arg His  
 1290 1295 1300

cgg aat act gtg gtg taa gctcagttgt gggttttttag gtggagagac acacctgctc 4000  
 Arg Asn Thr Val Val  
 1305

caatttcccc accccctct ctttctctgg tggctttcct tctaccccaa ggccagtagt 4060

tttgacactt cccagtggaa gatacagaga tgcaatgata gttatgtgct tacctaactt 4120

gaacattaga gggaaagact gaaagagaaa gataggagga accacaatgt ttcttcattt 4180

ctctgcatgg gttggtcagg agaatgaaac agctagagaa ggaccagaaa atgtaaggca 4240

atgctgccta ctatcaaact agctgtcact ttttttcttt ttctttttct ttctttgttt 4300

ctttcttctt cttctttttt tttttttttt taaagcagat ggttgaaaca cccatgctat 4360

ctgttcttat ctgcaggaac tgatgtgtgc atatttagca tccctggaaa tcataataaa 4420

gtttccatta gaacaaaaga ataacatttt ctataacata tgatagtgtc tgaaattgag 4480

aatccagttt ctttccccag cagtttctgt cctagcaagt aagaatggcc aactcaactt 4540

tcataattta aaaatctcca ttaaagttat aactagtaat tatgttttca acactttttg 4600

gtttttttca ttttgttttg ctctgaccga ttcctttata tttgctcccc tatttttggc 4660

tttaatttct aattgcaaag atgtttacat caaagcttct tcacagaatt taagcaagaa 4720

atattttaat atagtgaat ggccactact ttaagtatac aatctttaaa ataagaaagg 4780

gaggctaata tttttcatgc tatcaaatta tcttcaccct catcctttac atttttcaac 4840

attttttttt ctccataaat gacactactt gataggccgt tggttgtctg aagagtagaa 4900

U.S. Pat. & Tm. Off.

Sequence = 3690

gggaaactaa gagacagttc tctgtggttc aggaaaacta ctgatacttt caggggtggc 4960  
ccaatgaggg aatccattga actggaagaa acacactgga ttgggtatgt ctacctggca 5020  
gatactcaga aatgtagttt gcacttaagc tgtaatttta tttgttcttt ttctgaactc 5080  
cattttggat tttgaatcaa gcaatatgga agcaaccagc aaattaacta atttaagtac 5140  
atttttaaaa aaagagctaa gataaagact gtggaaatgc caaaccaagc aaattaggaa 5200  
ccttgcaacg gtatccaggg actatgatga gaggccagca cattatcttc atatgtcacc 5260  
tttgctacgc aaggaaattt gttcagttcg tatacttcgt aagaaggaat gcgagtaagg 5320  
attggcttga attccatgga atttctagta tgagactatt tatatgaagt agaaggtaac 5380  
tctttgcaca taaattggta taataaaaag aaaaacacaa acattcaaag cttagggata 5440  
ggtccttggg tcaaaagttg taaataaatg tgaaacatct tctc 5484

<210> 18  
<211> 3690  
<212> DNA  
<213> Mus musculus

<220>  
<221> CDS  
<222> (256)...(3690)

<400> 18  
ctggaggggt ataaatacct gatggctgct gccaggggtca caactttaca gggagttgaa 60  
gactgagact ctggccccac gggacacagt gtcactgggt tgaaacttct cagccacctt 120  
gggtgaaggga ctgagctggt agagacactt ctgaggctcc tcacgcttgg gtcttgttca 180  
ctccacggag tagcctagtc aactgcaaga gaacggagaa cgttggatth ggagcagaag 240  
tgcaaagtct cagac atg gct tgc ccc tgg aag ttt ctc ttc aaa gtc aaa 291  
Met Ala Cys Pro Trp Lys Phe Leu Phe Lys Val Lys

tcc tac caa agt gac ctg aaa gag gaa aag gac att aac aac aac gtg 339  
 Ser Tyr Gln Ser Asp Leu Lys Glu Glu Lys Asp Ile Asn Asn Asn Val  
 15 20 25

aag aaa acc cct tgt gct gtt ctc agc cca aca ata caa gat gac cct 387  
 Lys Lys Thr Pro Cys Ala Val Leu Ser Pro Thr Ile Gln Asp Asp Pro  
 30 35 40

aag agt cac caa aat ggc tcc ccg cag ctc ctc act ggg aca gca cag 435  
 Lys Ser His Gln Asn Gly Ser Pro Gln Leu Leu Thr Gly Thr Ala Gln  
 45 50 55 60

aat gtt cca gaa tcc ctg gac aag ctg cat gtg aca tcg acc cgt cca 483  
 Asn Val Pro Glu Ser Leu Asp Lys Leu His Val Thr Ser Thr Arg Pro  
 65 70 75

cag tat gtg agg atc aaa aac tgg ggc agt gga gag att ttg cat gac 531  
 Gln Tyr Val Arg Ile Lys Asn Trp Gly Ser Gly Glu Ile Leu His Asp  
 80 85 90

act ctt cac cac aag gcc aca tcg gat ttc act tgc aag tcc aag tct 579  
 Thr Leu His His Lys Ala Thr Ser Asp Phe Thr Cys Lys Ser Lys Ser  
 95 100 105

tgc ttg ggg tcc atc atg aac ccc aag agt ttg acc aga gga ccc aga 627  
 Cys Leu Gly Ser Ile Met Asn Pro Lys Ser Leu Thr Arg Gly Pro Arg  
 110 115 120

gac aag cct acc cct ctg gag gag ctc ctg cct cat gcc att gag ttc 675  
 Asp Lys Pro Thr Pro Leu Glu Glu Leu Leu Pro His Ala Ile Glu Phe  
 125 130 135 140

atc aac cag tat tat ggc tcc ttt aaa gag gca aaa ata gag gaa cat 723  
 Ile Asn Gln Tyr Tyr Gly Ser Phe Lys Glu Ala Lys Ile Glu Glu His  
 145 150 155

ctg gcc agg ctg gaa gct gta aca aag gaa ata gaa aca aca gga acc 771  
 Leu Ala Arg Leu Glu Ala Val Thr Lys Glu Ile Glu Thr Thr Gly Thr  
 160 165 170

tac cag ctc act ctg gat gag ctc atc ttt gcc acc aag atg gcc tgg 819  
 Tyr Gln Leu Thr Leu Asp Glu Leu Ile Phe Ala Thr Lys Met Ala Trp  
 175 180 185

agg	aat	gcc	cct	cgc	tgc	atc	ggc	agg	atc	cag	tgg	tcc	aac	ctg	cag	867
Arg	Asn	Ala	Pro	Arg	Cys	Ile	Gly	Arg	Ile	Gln	Trp	Ser	Asn	Leu	Gln	
190			195			200										
gtc	ttt	gac	gct	cgg	aac	tgt	agc	aca	gca	cag	gaa	atg	ttt	cag	cac	915
Val	Phe	Asp	Ala	Arg	Asn	Cys	Ser	Thr	Ala	Gln	Glu	Met	Phe	Gln	His	
205			210			215			220							
atc	tgc	aga	cac	ata	ctt	tat	gcc	acc	aac	aat	ggc	aac	atc	agg	tcg	963
Ile	Cys	Arg	His	Ile	Leu	Tyr	Ala	Thr	Asn	Asn	Gly	Asn	Ile	Arg	Ser	
225				230				235								
gcc	atc	act	gtg	ttc	ccc	cag	cgg	agt	gac	ggc	aaa	cat	gac	ttc	agg	1011
Ala	Ile	Thr	Val	Phe	Pro	Gln	Arg	Ser	Asp	Gly	Lys	His	Asp	Phe	Arg	
240			245			250										
ctc	tgg	aat	tca	cag	ctc	atc	cgg	tac	gct	ggc	tac	cag	atg	ccc	gat	1059
Leu	Trp	Asn	Ser	Gln	Leu	Ile	Arg	Tyr	Ala	Gly	Tyr	Gln	Met	Pro	Asp	
255			260			265										
ggc	acc	atc	aga	ggg	gat	gct	gcc	acc	ttg	gag	ttc	acc	cag	ttg	tgc	1107
Gly	Thr	Ile	Arg	Gly	Asp	Ala	Ala	Thr	Leu	Glu	Phe	Thr	Gln	Leu	Cys	
270			275			280										
atc	gac	cta	ggc	tgg	aag	ccc	cgc	tat	ggc	cgc	ttt	gat	gtg	ctg	cct	1155
Ile	Asp	Leu	Gly	Trp	Lys	Pro	Arg	Tyr	Gly	Arg	Phe	Asp	Val	Leu	Pro	
285			290			295			300							
ctg	gtc	ttg	caa	gct	gat	ggc	caa	gat	cca	gag	gtc	ttt	gaa	atc	cct	1203
Leu	Val	Leu	Gln	Ala	Asp	Gly	Gln	Asp	Pro	Glu	Val	Phe	Glu	Ile	Pro	
305				310				315								
cct	gat	ctt	gtg	ttg	gag	gtg	acc	atg	gag	cat	ccc	aag	tac	gag	tgg	1251
Pro	Asp	Leu	Val	Leu	Glu	Val	Thr	Met	Glu	His	Pro	Lys	Tyr	Glu	Trp	
320			325			330										
ttc	cag	gag	ctc	ggg	ttg	aag	tgg	tat	gca	ctg	cct	gcc	gtg	gcc	aac	1299
Phe	Gln	Glu	Leu	Gly	Leu	Lys	Trp	Tyr	Ala	Leu	Pro	Ala	Val	Ala	Asn	
335			340			345										
atg	cta	ctg	gag	gtg	ggc	ggc	ctc	gaa	ttc	cca	gcc	tgc	ccc	ttc	aat	1347
Met	Leu	Leu	Glu	Val	Gly	Gly	Leu	Glu	Phe	Pro	Ala	Cys	Pro	Phe	Asn	
350			355			360										



ggt	tgg	tac	atg	ggc	acc	gag	att	gga	gtt	cga	gac	ttc	tgt	gac	aca	1395
Gly	Trp	Tyr	Met	Gly	Thr	Glu	Ile	Gly	Val	Arg	Asp	Phe	Cys	Asp	Thr	
365					370					375					380	
cag	cgc	tac	aac	atc	ctg	gag	gaa	gtg	ggc	cga	agg	atg	ggc	ctg	gag	1443
Gln	Arg	Tyr	Asn	Ile	Leu	Glu	Glu	Val	Gly	Arg	Arg	Met	Gly	Leu	Glu	
				385					390					395		
acc	cac	aca	ctg	gcc	tcc	ctc	tgg	aaa	gac	cgg	gct	gtc	acg	gag	atc	1491
Thr	His	Thr	Leu	Ala	Ser	Leu	Trp	Lys	Asp	Arg	Ala	Val	Thr	Glu	Ile	
			400					405					410			
aat	gtg	gct	gtg	ctc	cat	agt	ttc	cag	aag	cag	aat	gtg	acc	atc	atg	1539
Asn	Val	Ala	Val	Leu	His	Ser	Phe	Gln	Lys	Gln	Asn	Val	Thr	Ile	Met	
		415					420					425				
gac	cac	cac	aca	gcc	tca	gag	tcc	ttc	atg	aag	cac	atg	cag	aat	gag	1587
Asp	His	His	Thr	Ala	Ser	Glu	Ser	Phe	Met	Lys	His	Met	Gln	Asn	Glu	
	430					435					440					
tac	cgg	gcc	cgt	gga	ggc	tgc	ccg	gca	gac	tgg	att	tgg	ctg	gtc	cct	1635
Tyr	Arg	Ala	Arg	Gly	Gly	Cys	Pro	Ala	Asp	Trp	Ile	Trp	Leu	Val	Pro	
445					450					455					460	
cca	gtg	tct	ggg	agc	atc	acc	cct	gtg	ttc	cac	cag	gag	atg	ttg	aac	1683
Pro	Val	Ser	Gly	Ser	Ile	Thr	Pro	Val	Phe	His	Gln	Glu	Met	Leu	Asn	
			465						470					475		
tat	gtc	cta	tct	cca	ttc	tac	tac	tac	cag	atc	gag	ccc	tgg	aag	acc	1731
Tyr	Val	Leu	Ser	Pro	Phe	Tyr	Tyr	Tyr	Gln	Ile	Glu	Pro	Trp	Lys	Thr	
			480					485					490			
cac	atc	tgg	cag	aat	gag	aag	ctg	agg	ccc	agg	agg	aga	gag	atc	cga	1779
His	Ile	Trp	Gln	Asn	Glu	Lys	Leu	Arg	Pro	Arg	Arg	Arg	Glu	Ile	Arg	
		495					500					505				
ttt	aga	gtc	ttg	gtg	aaa	gtg	gtg	ttc	ttt	gct	tcc	atg	cta	atg	cga	1827
Phe	Arg	Val	Leu	Val	Lys	Val	Val	Phe	Phe	Ala	Ser	Met	Leu	Met	Arg	
	510					515					520					
aag	gtc	atg	gct	tca	cgg	gtc	aga	gcc	aca	gtc	ctc	ttt	gct	act	gag	1875
Lys	Val	Met	Ala	Ser	Arg	Val	Arg	Ala	Thr	Val	Leu	Phe	Ala	Thr	Glu	
525					530					535					540	

aca	ggg	aag	tct	gaa	gca	cta	gcc	agg	gac	ctg	gcc	acc	ttg	ttc	agc	1923
Thr	Gly	Lys	Ser	Glu	Ala	Leu	Ala	Arg	Asp	Leu	Ala	Thr	Leu	Phe	Ser	
				545					550					555		
tac	gcc	ttc	aac	acc	aag	gtt	gtc	tgc	atg	gac	cag	tat	aag	gca	agc	1971
Tyr	Ala	Phe	Asn	Thr	Lys	Val	Val	Cys	Met	Asp	Gln	Tyr	Lys	Ala	Ser	
			560					565					570			
acc	ttg	gaa	gag	gag	caa	cta	ctg	ctg	gtg	gtg	aca	agc	aca	ttt	ggg	2019
Thr	Leu	Glu	Glu	Glu	Gln	Leu	Leu	Leu	Val	Val	Thr	Ser	Thr	Phe	Gly	
		575					580					585				
aat	gga	gac	tgt	ccc	agc	aat	ggg	cag	act	ctg	aag	aaa	tct	ctg	ttc	2067
Asn	Gly	Asp	Cys	Pro	Ser	Asn	Gly	Gln	Thr	Leu	Lys	Lys	Ser	Leu	Phe	
	590					595				600						
atg	ctt	aga	gaa	ctc	aac	cac	acc	ttc	agg	tat	gct	gtg	ttt	ggc	ctt	2115
Met	Leu	Arg	Glu	Leu	Asn	His	Thr	Phe	Arg	Tyr	Ala	Val	Phe	Gly	Leu	
605				610					615					620		
ggc	tcc	agc	atg	tac	cct	cag	ttc	tgc	gcc	ttt	gct	cat	gac	atc	gac	2163
Gly	Ser	Ser	Met	Tyr	Pro	Gln	Phe	Cys	Ala	Phe	Ala	His	Asp	Ile	Asp	
			625					630					635			
cag	aag	ctg	tcc	cac	ctg	gga	gcc	tct	cag	ctt	gcc	cca	aca	gga	gaa	2211
Gln	Lys	Leu	Ser	His	Leu	Gly	Ala	Ser	Gln	Leu	Ala	Pro	Thr	Gly	Glu	
		640				645					650					
ggg	gac	gaa	ctc	agt	ggg	cag	gag	gat	gcc	ttc	cgc	agc	tgg	gct	gta	2259
Gly	Asp	Glu	Leu	Ser	Gly	Gln	Glu	Asp	Ala	Phe	Arg	Ser	Trp	Ala	Val	
	655					660					665					
caa	acc	ttc	cgg	gca	gcc	tgt	gag	acc	ttt	gat	gtc	cga	agc	aaa	cat	2307
Gln	Thr	Phe	Arg	Ala	Ala	Cys	Glu	Thr	Phe	Asp	Val	Arg	Ser	Lys	His	
	670					675				680						
cac	att	cag	atc	ccg	aaa	cgc	ttc	act	tcc	aat	gca	aca	tgg	gag	cca	2355
His	Ile	Gln	Ile	Pro	Lys	Arg	Phe	Thr	Ser	Asn	Ala	Thr	Trp	Glu	Pro	
685				690					695					700		
cag	caa	tat	agg	ctc	atc	cag	agc	ccg	gag	cct	tta	gac	ctc	aac	aga	2403
Gln	Gln	Tyr	Arg	Leu	Ile	Gln	Ser	Pro	Glu	Pro	Leu	Asp	Leu	Asn	Arg	
			705					710					715			

gcc	ctc	agc	agc	atc	cat	gca	aag	aac	gtg	ttt	acc	atg	agg	ctg	aaa	2451	
Ala	Leu	Ser	Ser	Ile	His	Ala	Lys	Asn	Val	Phe	Thr	Met	Arg	Leu	Lys		
			720						725						730		
tcc	cag	cag	aat	ctg	cag	agt	gaa	aag	tcc	agc	cgc	acc	acc	ctc	ctc	2499	
Ser	Gln	Gln	Asn	Leu	Gln	Ser	Glu	Lys	Ser	Ser	Arg	Thr	Thr	Leu	Leu		
			735						740						745		
gtt	cag	ctc	acc	ttc	gag	ggc	agc	cga	ggg	ccc	agc	tac	ctg	cct	ggg	2547	
Val	Gln	Leu	Thr	Phe	Glu	Gly	Ser	Arg	Gly	Pro	Ser	Tyr	Leu	Pro	Gly		
			750						755						760		
gaa	cac	ctg	ggg	atc	ttc	cca	ggc	aac	cag	acc	gcc	ctg	gtg	cag	gga	2595	
Glu	His	Leu	Gly	Ile	Phe	Pro	Gly	Asn	Gln	Thr	Ala	Leu	Val	Gln	Gly		
765						770						775			780		
atc	ttg	gag	cga	gtt	gtg	gat	tgt	cct	aca	cca	cac	caa	act	gtg	tgc	2643	
Ile	Leu	Glu	Arg	Val	Val	Asp	Cys	Pro	Thr	Pro	His	Gln	Thr	Val	Cys		
			785						790						795		
ctg	gag	gtt	ctg	gat	gag	agc	ggc	agc	tac	tgg	gtc	aaa	gac	aag	agg	2691	
Leu	Glu	Val	Leu	Asp	Glu	Ser	Gly	Ser	Tyr	Trp	Val	Lys	Asp	Lys	Arg		
			800						805						810		
ctg	ccc	ccc	tgc	tca	ctc	agc	caa	gcc	ctc	acc	tac	ttc	ctg	gac	att	2739	
Leu	Pro	Pro	Cys	Ser	Leu	Ser	Gln	Ala	Leu	Thr	Tyr	Phe	Leu	Asp	Ile		
			815						820						825		
acg	acc	cct	ccc	acc	cag	ctg	cag	ctc	cac	aag	ctg	gct	cgc	ttt	gcc	2787	
Thr	Thr	Pro	Pro	Thr	Gln	Leu	Gln	Leu	His	Lys	Leu	Ala	Arg	Phe	Ala		
830						835						840					
acg	gac	gag	acg	gat	agg	cag	aga	ttg	gag	gcc	ttg	tgt	cag	ccc	tca	2835	
Thr	Asp	Glu	Thr	Asp	Arg	Gln	Arg	Leu	Glu	Ala	Leu	Cys	Gln	Pro	Ser		
845						850						855			860		
gag	tac	aat	gac	tgg	aag	ttc	agc	aac	aac	ccc	acg	ttc	ctg	gag	gtg	2883	
Glu	Tyr	Asn	Asp	Trp	Lys	Phe	Ser	Asn	Asn	Pro	Thr	Phe	Leu	Glu	Val		
			865						870						875		
ctt	gaa	gag	ttc	cct	tcc	ttg	cat	gtg	ccc	gct	gcc	ttc	ctg	ctg	tcg	2931	
Leu	Glu	Glu	Phe	Pro	Ser	Leu	His	Val	Pro	Ala	Ala	Phe	Leu	Leu	Ser		
			880						885						890		

cag	ctc	cct	atc	ttg	aag	ccc	cgc	tac	tac	tcc	atc	agc	tcc	tcc	cag	2979	
Gln	Leu	Pro	Ile	Leu	Lys	Pro	Arg	Tyr	Tyr	Ser	Ile	Ser	Ser	Ser	Gln		
895						900						905					
gac	cac	acc	ccc	tcg	gag	gtt	cac	ctc	act	gtg	gcc	gtg	gtc	acc	tac	3027	
Asp	His	Thr	Pro	Ser	Glu	Val	His	Leu	Thr	Val	Ala	Val	Val	Thr	Tyr		
910						915						920					
cgc	acc	cga	gat	ggg	cag	ggg	ccc	ctg	cac	cat	ggg	gtc	tgc	agc	act	3075	
Arg	Thr	Arg	Asp	Gly	Gln	Gly	Pro	Leu	His	His	Gly	Val	Cys	Ser	Thr		
925				930				935						940			
tgg	atc	agg	aac	ctg	aag	ccc	cag	gac	cca	gtg	ccc	tgc	ttt	gtg	cga	3123	
Trp	Ile	Arg	Asn	Leu	Lys	Pro	Gln	Asp	Pro	Val	Pro	Cys	Phe	Val	Arg		
			945						950						955		
agt	gtc	agt	ggc	ttc	cag	ctc	cct	gag	gac	ccc	tcc	cag	cct	tgc	atc	3171	
Ser	Val	Ser	Gly	Phe	Gln	Leu	Pro	Glu	Asp	Pro	Ser	Gln	Pro	Cys	Ile		
			960						965						970		
ctc	att	ggg	cct	ggg	acg	ggc	att	gct	ccc	ttc	cga	agt	ttc	tgg	cag	3219	
Leu	Ile	Gly	Pro	Gly	Thr	Gly	Ile	Ala	Pro	Phe	Arg	Ser	Phe	Trp	Gln		
975						980						985					
cag	cgg	ctc	cat	gac	tcc	cag	cac	aaa	ggg	ctc	aaa	gga	ggc	cgc	atg	3267	
Gln	Arg	Leu	His	Asp	Ser	Gln	His	Lys	Gly	Leu	Lys	Gly	Gly	Arg	Met		
990						995						1000					
agc	ttg	gtg	ttt	ggg	tgc	cgg	cac	ccg	gag	gag	gac	cac	ctc	tat	cag	3315	
Ser	Leu	Val	Phe	Gly	Cys	Arg	His	Pro	Glu	Glu	Asp	His	Leu	Tyr	Gln		
1005				1010				1015						1020			
gaa	gaa	atg	cag	gag	atg	gtc	cgc	aag	aga	gtg	ctg	ttc	cag	gtg	cac	3363	
Glu	Glu	Met	Gln	Glu	Met	Val	Arg	Lys	Arg	Val	Leu	Phe	Gln	Val	His		
			1025						1030						1035		
aca	ggc	tac	tcc	cgg	ctg	ccc	ggc	aaa	ccc	aag	gtc	tac	gtt	cag	gac	3411	
Thr	Gly	Tyr	Ser	Arg	Leu	Pro	Gly	Lys	Pro	Lys	Val	Tyr	Val	Gln	Asp		
			1040						1045						1050		
atc	ctg	caa	aag	cag	ctg	gcc	aat	gag	gta	ctc	agc	gtg	ctc	cac	ggg	3459	
Ile	Leu	Gln	Lys	Gln	Leu	Ala	Asn	Glu	Val	Leu	Ser	Val	Leu	His	Gly		
1055						1060						1065					

gag cag ggc cac ctc tac att tgc gga gat gtg cgc atg gct cgg gat 3507  
 Glu Gln Gly His Leu Tyr Ile Cys Gly Asp Val Arg Met Ala Arg Asp  
 1070 1075 1080

gtg gct acc aca ttg aag aag ctg gtg gcc acc aag ctg aac ttg agc 3555  
 Val Ala Thr Thr Leu Lys Lys Leu Val Ala Thr Lys Leu Asn Leu Ser  
 1085 1090 1095 1100

gag gag cag gtg gaa gac tat ttc ttc cag ctc aag agc cag aaa cgt 3603  
 Glu Glu Gln Val Glu Asp Tyr Phe Phe Gln Leu Lys Ser Gln Lys Arg  
 1105 1110 1115

tat cat gaa gat atc ttc ggt gca gtc ttt tcc tat ggg gca aaa aag 3651  
 Tyr His Glu Asp Ile Phe Gly Ala Val Phe Ser Tyr Gly Ala Lys Lys  
 1120 1125 1130

ggc agc gcc ttg gag gag ccc aaa gcc acg agg ctc tga 3690  
 Gly Ser Ala Leu Glu Glu Pro Lys Ala Thr Arg Leu  
 1135 1140 1145

<210> 19

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 19

catcaaaggt ggccgaga

18

<210> 20

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 20

ctgtctagaa ctgcccag

18

<210> 21

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 21

tgccttgaga acttcggg

18

<210> 22

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 22

tgtcacttat ctggattt

18

<210> 23

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 23

cttgaacaga aatttcca

18

<210> 24

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 24

tctccacatt gttgttga

18

<210> 25

Approved for Release

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 25

ctgaggttgt gatactga

18

<210> 26

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 26

agcttgacca gagattct

18

<210> 27

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 27

gtgaagtgtg tcttgga

18

<210> 28

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 28

gcaagatttg gacctgca

18

<210> 29

Sequence

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 29

ccctgggtcc tctggtca

18

<210> 30

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 30

gccgtaatat tggttgac

18

<210> 31

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 31

ctcctttggt accgcttc

18

<210> 32

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 32

gctcatctcc cgtcagtt

18

<210> 33

ccctgggtcc tctggtca



<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 33

agacctgcag gttggacc

18

<210> 34

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 34

cgtgtctgca gatgtgtt

18

<210> 35

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 35

aagtcgtgct tgccatca

18

<210> 36

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 36

cctctgatgc tgccatct

18

<210> 37

Sequence Listing

<210> 41

[illegible]

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 41

ctgcccactt cctccagg

18

<210> 42

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 42

ttgatctcaa cgacagcc

18

<210> 43

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 43

tccatgatgg tcacattc

18

<210> 44

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 44

ggaccggtat tcattctg

18

<210> 45

Approved for Release

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 45

acgtagttca gcatctcc

18

<210> 46

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 46

gggtctccgc ttctcgtc

18

<210> 47

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 47

agcatacagg caaagagc

18

<210> 48

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 48

tgtctctgtc gcaaagag

18

<210> 49

U.S. PAT. & TM. OFFICE

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 49

ttcctcctcc aggcagct

18

<210> 50

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 50

ccattgccag ggcagtct

18

<210> 51

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 51

acacagcgta cctgaatt

18

<210> 52

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 52

gcttctgatc aatgtcat

18

<210> 53

U.S. Pat. No. 6,666,666

<210> 57

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 57

agttctgtgc cggcagct

18

<210> 58

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 58

acctcagata atgcagag

18

<210> 59

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 59

agatcccgtg ctgacaat

18

<210> 60

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 60

ctcaccaga cccaaagt

18

<210> 61

Sequence

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 61

gtccccgccg ccacgaga

18

<210> 62

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 62

actgactgag aatcgctg

18

<210> 63

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 63

ctgctgttcc aggtcaga

18

<210> 64

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 64

gttatctcca gggtgccc

18

<210> 65

Sequence = 63000000



<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 65

ccggttggtgc tcaatgct

18

<210> 66

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 66

caggtaacga aactgatt

18

<210> 67

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 67

attctccaga ggcaggta

18

<210> 68

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 68

tcataaagtt ttgtccca

18

<210> 69

U.S. Pat. No. 6,000,000

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 69

agtccaaagt ttccatct

18

<210> 70

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 70

tttaggattt ctgtcaag

18

<210> 71

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 71

tacatagact ccaccatt

18

<210> 72

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 72

aactaccatt tgttgaca

18

<210> 73

Sequence = 3000000

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 73

tccacatcct gaactacc

18

<210> 74

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 74

ggcaatgatt ttctgtgg

18

<210> 75

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 75

gtccttgatca aagtctgg

18

<210> 76

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 76

gtagcatctg ccgtcaca

18

<210> 77

Approved for Release

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 77

gcctccagca cattctcg

18

<210> 78

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 78

ggtcctgagc agcctcca

18

<210> 79

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 79

ggcaaagcag tctgtgtc

18

<210> 80

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 80

aggtggttgg attgtaga

18

<210> 81

Sequence

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 81

attgtgctcc agttgaaa

18

<210> 82

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 82

tgtggacatt tcttgaca

18

<210> 83

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 83

tagggcaggc acgcacac

18

<210> 84

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 84

ttaatcccat tttcttct

18

<210> 85

OFFICIAL

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 85

tgatcctgtg ccaatgcc

18

<210> 86

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 86

ctgggtctat ggcttcaa

18

<210> 87

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 87

gacgttcagt ttctctgg

18

<210> 88

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 88

ggataagcaa ggacaggc

18

<210> 89

RTS-0066-52-PATENT

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 89

actggaactg tagagagg

18

<210> 90

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 90

agggttgctgt tgtcagta

18

<210> 91

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 91

gttaatggta tgataata

18

<210> 92

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 92

ttctctgggtt gattgtgc

18

<210> 93

U.S. Pat. No. 6,600,000

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 93

ttactattct ctggttga

18

<210> 94

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 94

ctggaacaca gatggttg

18

<210> 95

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 95

caggtcccca acagccat

18

<210> 96

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 96

tactgaagcg gcgacacg

18

<210> 97

Approved for Release



<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 97

aggttacaag actctatg

18

<210> 98

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 98

tggagccatt ctcaaact

18

<210> 99

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 99

aggccatctt ccattctt

18

<210> 100

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 100

ctagtgggac cgttacac

18

<210> 101

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 101

tcagaccac aatgacca

18

<210> 102

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 102

atgctcttcc ttctaaca

18

<210> 103

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 103

ctgtgccact gggagtta

18

<210> 104

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 104

ccaaaagcac ctgagcca

18

<210> 105

Approved for Release

<210> 109

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 109

tcctccatca gcattgta

18

<210> 110

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 110

ccaaaggtca tcagttcc

18

<210> 111

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 111

catccaacat ttgaccat

18

<210> 112

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 112

actcagcagc cagttcct

18

<210> 113

Attorney's Office

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 113

gtcatttgga ctgggaag

18

<210> 114

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 114

ttccaaatcc tcttcac

18

<210> 115

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 115

gaggtgggat gttgaaag

18

<210> 116

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 116

cagcaaaacc tccatctc

18

<210> 117

Approved for Release

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 117

ctcagcagta gcaccctg

18

<210> 118

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 118

tgggtgctac tgcctct

18

<210> 119

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 119

gtttgtctcg cataggag

18

<210> 120

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 120

ccactggatt caggtatt

18

<210> 121

Approved for Release

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 121

ggctcattca cataactca

18

<210> 122

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 122

ttgacagtat gttgttct

18

<210> 123

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 123

ttccagtagt cagggttg

18

<210> 124

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 124

tgctgaaggg tgctccga

18

<210> 125

sequence

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 125

aggtattcag gattctct

18

<210> 126

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 126

tctgtaaggt ggaggcgg

18

<210> 127

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 127

agtggtcaaaa ctactggc

18

<210> 128

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 128

gttcaagtta ggtaagca

18

<210> 129

Approved for Release



<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 129

ctatctttct ctttcagt

18

<210> 130

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 130

atgcagagaa atgaagaa

18

<210> 131

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 131

cagcattgcc ttacattt

18

<210> 132

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 132

gtgtttcaac catctgct

18

<210> 133

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 133

tttgttctaa tggaaact

18

<210> 134

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 134

cagagcaaaa caaaatga

18

<210> 135

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 135

aggatgaggg tgaagata

18

<210> 136

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 136

tactcttcag acaaccaa

18

<210> 137

Approved for Release

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 137

gttttcctga accacaga

18

<210> 138

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 138

acatacccaa tccagtgt

18

<210> 139

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 139

aaaatggagt tcagaaaa

18

<210> 140

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 140

gcctctcatc atagtccc

18

<210> 141

g t t t c c t g a a c c a c a g a

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 141

gagttacctt ctacttca

18

<210> 142

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 142

cacatttatt tacaactt

18

<210> 143

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 143

gtaaagttgt gaccctggca

20

<210> 144

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 144

ttgcatttct gtcctaaatc

20

<210> 145

Sequence

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 145

ttggtaggat ttgactttga

20

<210> 146

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 146

ctcttagggt catcttgat

20

<210> 147

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 147

tcgatgtcac atgcagcttg

20

<210> 148

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 148

tgaaatccga tgtggccttg

20

<210> 149

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 149

gggtaggctt gtctctgggt

20

<210> 150

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 150

gcatgaggca ggagctcctc

20

<210> 151

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 151

ttcctccagg ccatcttggt

20

<210> 152

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 152

atgagctgtg aattccagag

20

<210> 153

Approved for Release

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 153

cttccagcct aggtcgatgc

20

<210> 154

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 154

atttcaaaga cctctggatc

20

<210> 155

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 155

ctccagtagc atgttgcca

20

<210> 156

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 156

ccagagggag gccagtgtgt

20

<210> 157

U.S. Pat. No. 6,666,666

<210> 161



<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 161

tctaaatcgg atctctctcc

20

<210> 162

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 162

agtagcaaag aggactgtgg

20

<210> 163

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 163

tgcttggtcac caccagcagt

20

<210> 164

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 164

actgagggta catgctggag

20

<210> 165

Sequence

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 165

gctgcggaag gcacccctct

20

<210> 166

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 166

ctggatgagc ctatattgct

20

<210> 167

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 167

tgctgagggc tctgttgagg

20

<210> 168

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 168

ggctggactt ttcactctgc

20

<210> 169

Approved for Release

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 169

gtagctgggc cctcggctgc

20

<210> 170

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 170

gtgtaggaca atccacaact

20

<210> 171

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 171

tgagggcttg gctgagtgag

20

<210> 172

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 172

aggcctccaa tctctgccta

20

<210> 173

sequence

20

20

20

20

<210> 177

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 177

gcacccaaac accaagctca

20

<210> 178

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 178

agcctgtgtg cacctggaac

20

<210> 179

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 179

ctgaacgtag accttggtt

20

<210> 180

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 180

accagcttct tcaatgtggt

20

<210> 181

Approved for Release

<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 181  
aagatatctt catgataacg 20

<210> 182  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 182  
agagcctcgt ggctttgggc 20

Sequence = 5'-3'